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ABSTRACT  
Health-related quality of life (HR-QOL) is a significant treatment outcome 
for persons with end-stage renal disease (ESRD); however, little is known about 
the HR-QOL of Mexican patients with ESRD. This pilot study describes 
relationships between demographics, sleep disorders, spirituality, mood, folk 
practices and dialysis modality on the HR-QOL of patients with ESRD residing in 
Guanajuato, Mexico.  
Mexican patients receiving continuous ambulatory peritoneal dialysis 
(CAPD), automated peritoneal dialysis (APD) and hemodialysis (HD) provided 
information on demographics, clinical health data including body mass index 
(BMI), and folk health practices. Measures included the Short Form (SF)-36 HR-
QOL survey, Sleep Habits Questionnaire, Latin Spirituality Perspective Scale and 
Hospital Anxiety and Depression Scale. Data were analyzed using SAS software 
(V9.1). Significance level for this pilot study was set at p<0.10. The Quality-
Adjusted Life Year method was utilized to examine cost effectiveness for each 
dialysis modality. 
Demographics and clinical data showed participants (N=121) to be 59 
(SD=13) years, predominantly men (55.4%), married (66.9%), Catholic (92.6%), 
and not currently working (78.3%). The majority were diabetic (72%) and slightly 
overweight (BMI M=26.1; SD=5.1). The CAPD group (n=39) demonstrated 
significantly lower HR-QOL scores compared to the APD (n=42) and HD (n=40) 
groups. Patients on HD reported higher rates and greater numbers of sleep 
disorders, including insomnia symptoms, non-restorative and insufficient sleep, 
  ii 
and daytime somnolence compared to patients on CAPD and APD. Patients on 
CAPD reported more anxiety and depression compared to patients on HD and 
APD. Overall linear regression for HR-QOL found dialysis type, sleep disorders 
and income to be significant predictors and the model accounted for 31% of the 
variance. Cost analysis indicated APD as the preferred treatment because it is less 
costly and results in the best HR-QOL compared to the other treatment 
modalities. 
Findings provide the first SF-36 norms for Mexicans with ESRD.  Sleep 
disorders and dialysis type greatly impinge on the HR-QOL of these patients, 
particularly their mental health. APD was identified as the preferred treatment 
based on low cost and improved HR-QOL. Results can inform clinical care and 
health policy for Mexican patients with ESRD.     
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Chapter 1 
INTRODUCTION 
Overview 
The increased prevalence of chronic diseases around the world has been 
well documented (Collins, Gilbertson, Snyder, Chen & Foley, 2010; Saran, 
Hedgeman, Huseini, Stack & Shahinian, 2010). The World Health Organization 
(WHO) has predicted the prevalence of type 2 diabetes to reach 366 million 
persons globally by 2030 (WHO, 2004). Type 2 diabetes is the leading cause of 
end-stage renal disease (ESRD) (Cusumano, García-García & González Bedat, 
2009; Mendez-Durán, Méndez-Bueno, Tapia-Yáñez, Muñoz-Montes & Aguilar-
Sánchez, 2010; Paniagua, Ramos, Fabian, Lagunas & Amato, 2007). In Mexico, 
the prevalence of type 2 diabetes is 14.4% (Instituto Nacional de Salud Pública, 
2011); it is predicted that 18% of the adult population in Mexico will have type 2 
diabetes by 2025 (Atkins & Zimmet, 2009). In 2007, the Mexican Kidney 
Foundation estimated that approximately 100,000 patients have ESRD. Of the 
Mexican patients receiving dialysis treatment, 80% were on Continued 
Ambulatory Peritoneal Dialysis (CAPD), 19% were on Hemodialysis (HD) and 
1% was on Automated Peritoneal Dialysis (APD) (Fundación Mexicana del 
Riñón, 2007; Nissenson, 1994).  
In the past, the intent of medical care for persons with ESRD was to 
improve survival. In recent years, however, the major treatment goal has been to 
improve their health-related quality of life (HR-QOL) (Harris, Lamping, Brown & 
Constantinovici, 2002). Thus, health services researchers have reported the need 
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to measure HR-QOL as a significant outcome for evaluating treatment of persons 
with ESRD (Anderson & Burckhardt, 1999). Patients‘ perceptions about their 
own wellness are also being recognized as an indicator to evaluate health care 
outcomes (Bakewell, Higgins, & Edmunds, 2002; Lii, Tsay, & Wang, 2007; 
Morsch, Goncalves, & Barros, 2006; Ware & Sherbourne, 1992;). Various HR-
QOL models have been published in order to achieve a better understanding that 
allows for evidence-based psychosocial interventions (Cummings, 2005; Ferrans, 
Zerwick, Wilbur & Larson, 2005; Haas, 1999; Joyce, Hickey, McGee & O‘Boyle, 
2003; Rapkin & Schwartz, 2004; Schwartzmann, 2003; Souza & Chen, 2002; 
Taillefer, Dupuis, Roberge & Le May, 2003; Ventegodt, Merrick & Andersen, 
2003; Wilson & Cleary, 1995).  
Goals, Specific Aims and Hypotheses 
Short-term goal. Perform a descriptive, cross-sectional study to examine 
associations between dialysis modality, demographic variables, sleep disorders, 
spiritual perspective, anxiety, depression, and folk practices on the HR-QOL of 
persons with ESRD residing in Guanajuato, Mexico. 
Long-term goal. Utilize findings from this descriptive study to develop 
targeted interventions for sleep disorders that may impact the HR-QOL of persons 
with ESRD on 3 types of dialysis thereby reducing future health care costs by 
improving sleep. 
Aim 1. To characterize the demographics, socioeconomic status (SES), 
health histories, prevalence rates and types of sleep disorders, folk practices used, 
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spiritual perspective, anxiety, depression, and HR-QOL scores of Mexicans with 
ESRD for each of 3 types of dialysis.  
Aim 1 is descriptive in nature, therefore; no hypotheses are specified. 
Aim 2. To analyze HR-QOL outcomes of Mexicans with ESRD on 3 
modalities of dialysis controlling for demographics, SES, sleep disorder types, 
spiritual perspectives.  
Research Question 1. Do HR-QOL, sleep disorders, spiritual perspective, 
anxiety, depression, and use of folk practices differ by dialysis modality? 
Hypothesis 1. HRQOL, sleep disorders, spirituality, anxiety, depression, and use 
of folk practices will differ by dialysis modality.  
 Aim 3.  To examine associations between cost effectiveness and dialysis 
modalities among Mexicans with ESRD.  
Aim 3 is descriptive in nature, therefore; no hypotheses are specified. 
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Chapter 2 
BACKGROUND LITERATURE 
End-Stage Renal Disease (ESRD)  
  End-stage renal disease has been globally recognized as a complicated 
disease. In 2008, the number of patients with the disease was projected to increase 
to more than 2 million by 2010 (Pecoits-Filho et al., 2008), but in 2009 it had 
already been calculated to be 2.5 million. Current studies have predicted the 
prevalence to be 5.5 million patients by 2030 (Meichelboeck, 2011).    
 In the United States (US), the adjusted incidence rate of ESRD in 2006 
reached 360 per million population (USRDS, 2008). After a 2.1% decline in 2007, 
it fell 1.1% in 2008, to 350.8 per million (USRDS, 2010). The prevalence rate for 
ESRD, adjusted for age, gender, and race rose 2.3% between 2005 and 2006 to 
reach 1,626 per million population (USRDS, 2008).  In 2007 and 2008, the 
adjusted rate of prevalent cases of ESRD rose 1.9% to 1,699 per million 
population. This rate is nearly 20% higher than in 2000. The annual rate of 
increase has remained between 1.9% and 2.3% since 2003 (USRDS, 2010). 
The increase in the incidence and prevalence of ESRD has resulted in 
significantly greater costs of care.  Total US Medicare spending in 2008 was 
reported to be nearly $453.9 billion. The costs for ESRD rose to $26.8 billion — 
5.9% of the entire Medicare budget, including Part D, and 6.6 % of the budget 
excluding Part D. This level has not changed over the past four years.  The 
stability of costs is a result of comparable growth in both the Medicare and ESRD 
programs, which has kept proportional costs constant (USRDS, 2010). 
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 Because renal transplant (RT) opportunities are relatively limited, 
hemodialysis (HD) is the initial treatment of choice for the majority of patients 
with ESRD in the US.  Approximately 94% of incident patients begin treatment 
with HD, amounting to 101,033 patients in 2008 (USRDS, 2010).  Ninety-two 
percent of prevalent patients on dialysis are prescribed this mode of therapy 
(347,150 patients as of 2008 [USRDS, 2010]).   
In Latin America, the prevalence and incidence of ESRD is variable, but 
the growth trend is similar to the US. As the distribution of patients by therapy 
and the sources of funding for dialysis therapy are determined by the local health 
care financial systems, they often vary widely from country to country. In 2006, 
Mexico reported the prevalence and incidence rates of ESRD of 510.4 and 345.9 
per million population, respectively. The lack of a formal national registry system 
in Mexico, however, could result in underestimation of these rates (Cusumano, et 
al., 2009). In 2005, the prevalence rate for creatinine clearance less than 15 
mL/min (considered as renal failure) was 1,142 per million population just in the 
Mexican state of Michoacan (Amato et al., 2005). Furthermore, in 2007 the 
Mexican Kidney Foundation reported 100,000 persons diagnosed with ESRD in 
Mexico (Fundación Mexicana del Riñón, 2007). These numbers are similar to the 
ESRD prevalence rates in developed countries.  The presence of malnutrition, 
diabetes, reduced access to high quality health care and a minimal 6% of the 
national gross product spent on health care in a developing country such as 
Mexico, are several factors that can influence clinical and HR-QOL outcomes 
(Cueto-Manzano & Rojas-Campos, 2007). 
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Mexican Health Care  
Health System. Figure 1 illustrates the organizational structure of the health 
insurance system in Mexico. The private sector in Mexico only covers 3% of the 
entire population, usually wealthy, private insurance or medical tourism (Whyte, 
2009). The public sector is the primary provider of health services for 55 million 
salaried workers in the formal sector, also called the social security institutions. 
The services are paid by the employee (according to their salary), the government, 
and the employer. The Mexican Institute of Social Security (IMSS) is the second 
largest provider with 44.5 million people. The Insurance and Social Service 
Institute for State Workers (ISSSTE) covers 10.6 million workers, followed by 
Petróleos Mexicanos (PEMEX) with 700,000 insured petroleum workers, then the 
Secretariat of National Defense (SEDENA) that covers 600,000 military and their 
dependents (Pan American Health Organization, 2007).  
Informal workers, rural populations, and the unemployed account for 45 
million people and are expected to be covered by the Seguro Popular (SP), a 
recent strategy that the Mexican Health Ministry has implemented to achieve 
universal coverage in Mexico. It is expected to change the entire health system 
structure (García-García, Reniorte-López & Márquez-Magaña, 2010) (See Figure 
2).  
ESRD Treatment. Treatment for ESRD has physiological, psychological, 
socio-economic, and spiritual implications for the individual, family, and 
community (Schatell & Witten, 2008). The number of patients receiving renal 
replacement in Mexico increased at an annual rate of 10% from 2001 to 2005 
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(Cueto-Manzano, et al., 2007). The most common treatment for ESRD in Mexico 
is continuous ambulatory peritoneal dialysis (CAPD), which is a manual therapy 
done at home 4 times a day using a double bag device to introduce and exchange 
the fluid through the abdomen. Another dialysis modality, the automated 
peritoneal dialysis (APD), was introduced in 1998 and has increasingly been 
implemented using a machine to assist delivery and drainage of dialysate to the 
peritoneal cavity during the night in the patient‘s home. The third modality, 
hemodialysis (HD), is performed in specialized centers or units next to the 
hospitals where the patients attend their programmed sessions 2-3 times per week, 
3-4 hours in length, day or night.  In 2007, the Mexican Kidney Foundation 
estimated that approximately 100,000 patients have ESRD. Of the Mexican 
patients receiving dialysis treatment, 80% were on CAPD, 19% were on HD and 
1% was on APD (Fundación Mexicana del Riñón, 2007). Although RT is the 
optimal intervention, there was only a 10% annual growth for this option from 
2001 to 2005 (Cueto-Manzano, et al., 2007).  
Cost Coverage for Dialysis. Seventy-five percent of the patients on PD 
are treated in the IMSS, 13% in the ISSSTE, 7% in what now would be SP, and 
5% in private settings. Sixty-eight percent of the patients on HD are treated in the 
IMSS, 8% in the ISSSTE, 3% SP, and 21% in private settings. García-García et 
al. (2010) have reported differences between uninsured and insured patients 
related to access to a renal replacement therapy. They found an incidence rate of 
99 versus 327 patients per million population and a prevalence rate of 166 versus 
939 patients per million population. The type and quality of care offered at the 
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different social security institutions is limited due to government economic 
constraints. The annual costs of treating ESRD estimated by Prieto, 
Bhattacharyya, Divino & Paniagua (2007) are $24,032 USD/patient and $15,724 
USD/patient for HD and PD, respectively. These costs included drugs, supplies, 
hospitalization, treatment-related infections, infrastructure and physician and 
nurse fees as direct treatment-related costs and the indirect costs related to work 
loss and patient transportation. 
The risk of death has been reported to be higher for patients on PD than 
for HD patients after 1 year (Jaar et al, 2005; McDonald, Marshall, Johnson & 
Polkinhorne, 2009) depending on age, time in dialysis, and presence of 
comorbidities (McDonald, 2009). Small differences were observed in the quality-
adjusted life year (QALY) score that compared PD versus HD on an ESRD 
population in the Netherlands; the long-term survival hazard radio favored PD 
(Eryavuz et al, 2008; Korevaar et al, 2003). 
There are medical and non-medical factors that influence the selection of 
the optimal renal replacement therapy for the patient with ESRD. The few 
possibilities of RT limit the options available to be HD or PD (CAPD/APD). 
Paniagua and colleagues (2007) indicated that only 35% of patients participated in 
modality selection. Generally, patients do not have the opportunity to choose the 
type of treatment because there may only be one modality available in the dialysis 
unit, or a relative or the physician made the decision for the patient. Few patients 
sign an informed consent, or have a clear understanding of treatment prior to 
having the catheter installed. Hence, in addition to multiple medications, dietary 
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restrictions, and comorbid conditions, these patients now confront a new and 
unknown situation with dialysis.  
According to Cueto-Manzano (2007), non-medical factors seem to be 
more significant than medical factors when prescribing a treatment to an ESRD 
patient in Mexico. Similar to other countries studied, patient characteristics like 
autonomy, scheduling, and maintaining their current lifestyle are major factors in 
patients‘ decisions about dialysis modality (Johansen, 2011). Nephrologists‘ 
recommendations, as recently observed in the Philippines, can also be based on 
overall cost, renal residual function preservation, patient preference, and 
availability of dialysis support staff (Cruz et al., 2011). 
Some security institutions in Mexico have a policy of using CAPD as the 
first line of treatment, and HD as a second option when PD fails. This should not 
be taken as a competition between therapies, but as suggested by Chaudhary, 
Sangha & Khanna (2011), as complementary therapies given the long-term goals 
for the patient. Thus, some of the compelling and constraining factors include 
financial, infrastructure, and human resources.  
End-stage renal disease and HR-QOL 
The intent of medical care in ESRD cannot be solely to improve survival. 
The effects of health, illness, impairment, and treatment on HR-QOL must be 
considered. It is measured by assessing physical, mental/cognitive, and social 
functioning, as well as cultural, emotional, spiritual, political, or societal attributes 
(Unruh, Weisbord & Kimmel, 2005). In chronic illnesses, however, it is difficult 
to say what it is health-related or non-health-related, as almost all areas of life are 
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affected by health (Ferrans, et al., 2005). Persons living daily with ESRD and its 
treatment have their own ―perceptions of their position in life in the context of the 
culture and value systems in which they live and in relation to their goals, 
expectations, standards, and concerns‖ (World Health Organization, 1995). 
Generally, persons with ESRD have reported poorer HR-QOL compared to the 
general population (Morales-Jaimes, Salazar-Martínez, Flores-Villegas, 
Bochicchio-Riccardelli & López-Caudana, 2007; Reina-Neyra, Cirera-Segura & 
Martin-Espejo, 2008; Rocco, Mercieri & Yavuzer, 2006; Rodríguez-Vidal et al. 
2005; Varela, Vázquez, Bolaños & Alonso, 2011). Older patients perceived their 
HR-QOL to be poorer than young patients with ESRD in some dimensions 
(Grincenkov, et al., 2011; Kusumoto, Marques, Hass & Rodrigues, 2008; Reina-
Neyra, 2008; Sandoval-Jurado, Ceballos-Martínez, Navarrete-Novello, González-
Hernández & Hernández-Collin, 2007; Wehbe, Salazar, Vaccaro, Wehbe & 
Guerrero, 2004). In some studies, women reported worse physical and/or mental 
health (Kusek et al., 2002; Santos, Daher, Silva, Liborio & Kerr, 2009) or worse 
overall HR-QOL (Gil-Cunqueiro et al, 2003; Wehbe et al, 2004), while men 
reported poorer physical health in other studies (Bakewell et al., 2002; Sandoval-
Jurado et al., 2007).  
The major impact of ESRD on the physical domain of HR-QOL is 
consistently cited (Esquivel-Molina et al, 2009; Shrestha, Ghotekar, Sharma, 
Shangwa & Karki, 2008). Morsch et al. (2006) found that the ESRD Severity 
Index was strongly related to physical functioning. In their follow-up mortality 
study, persons with ESRD who had subsequently died reported worse perception 
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of their physical functioning than those who survived. Lii et al. (2007) showed 
statistically significant improvement in the physical component of HR-QOL 
indices following a psychosocial intervention.   
With respect to emotional HR-QOL, Fowler and Bass (2006) reported a 
strong relationship between poorer HR-QOL and the degree to which emotions 
were provoked by having ESRD.  Rodríguez-Vidal et al. (2005) reported that 45% 
of their subjects recognized emotional problems in daily life, with role emotional 
and vitality as the most affected domains. Other factors that were related to HR-
QOL and mental health included depression (Cruz, Fleck, & Polanczyk, 2010; 
Esquivel-Molina et al., 2009; Lii et al, 2007; Morales-Jaimes et al., 2007; Varela 
et al., 2011; Vázquez et al., 2004), emotional defensiveness (Kaltsouda et al, 
2011), poor functional independence (Rocco et al., 2006), anxiety (Varela et al., 
2011;Vázquez, 2004), stress, affect and cognitive appraisal (Chan et al., 2011). 
 Relevant to the adequacy of dialysis, Martin and Thompson (2000) 
identified a single significant negative correlation between role physical and 
dialysis efficacy (Kt/V) whereas Paniagua, Amato, Vonesh, Guo, & Mujais 
(2005) reported no evidence of a long term benefit in HR-QOL on CAPD patients 
by increasing peritoneal small solute clearances. In their longitudinal study, Wu et 
al. (2004) found that SF-36 scores improved for HD patients at the end of one 
year, particularly vitality. This study also described significant independent 
predictors of higher physical health scores for patients on HD, including male sex, 
high serum albumin, less severe cardiac and pulmonary disease. On the other 
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hand, higher serum albumin, dialysis adequacy, and social support were 
significant predictors of better mental health scores for persons on HD. 
Spiritual beliefs are related to HR-QOL and may act as coping 
mechanisms for patients with ESRD (Finkelstein, West, Gobin, Finkelstein & 
Wuerth, 2007; Kimmel, Emont, Newmann, Danko & Moss, 2003; Patel, Shah, 
Peterson & Kimmel, 2002).  Patients in Taiwan on long-term HD who did not 
have strong spiritual beliefs showed worse HR-QOL scores (Tze-Wah et al., 
2009), whereas spiritual distress and low existential well-being were associated 
with poor HR-QOL in Canada (Davison & Jhangri, 2010). Women reported 
higher religious, existential, and spiritual well-being, suggesting a gender 
difference for patients living with ESRD (Tanyi & Werner, 2003; Tanyi & 
Werner, 2008). Spinale and colleagues (2008) found an association between 
spirituality and survival in HD patients who participated in religious activities; the 
authors indicated that this association was most likely due to the increased 
perception of social support. Taken together,  patients with ESRD appear to have 
unmet spiritual and supportive care needs that require a better understanding by 
health care professionals to guide interventions aimed at improving HR-QOL 
(Davison & Jhangri, 2010a). 
Health-related Quality of Life and Dialysis Modality 
Several extant studies have examined dialysis modality type on HR-QOL. 
Higher (better) scores for HR-QOL have been noted for PD compared to HD 
treatment for ESRD (Brown et al, 2010; Caballero-Morales, 2006; Frimat et al, 
2006; Fructuoso, Castro, Oliveira, Prata,& Morgado, 2011; Ginieri-Coccossis, 
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Theofilou, Synodinou, Tomaras & Soldatos, 2008; Harris, 2002; Juergensen, 
Wuerth, Finkelstein, Juergensen & Finkelstein, 2006; Kutner, 2005; Mittal, 2001; 
Shrestha et al., 2008; Wu, 2004; Wu et al., 2001). Kutner et al. (2005) reported 
higher scores in PD patients for effects of kidney disease, staff encouragement, 
and satisfaction with care scales. In addition, Harris et al. (2002) reported less 
annual mortality and hospitalization rates among  PD patients and another study 
reported the overall intention-to-treat mortality risk after dialysis initiation was 
8% lower in PD versus HD matched patients (Weinhandl et al., 2010). 
Alternatively, a recent Canadian study showed no significant difference between 
HD and PD incidence rate ratios, rates of infection-related hospitalizations, risk of 
access loss, modality change or death following hospitalization for infection 
(Williams, Quinn, Callery, Kiss & Oliver, 2010).  
Travel and fewer dietary restrictions, recreation, and dialysis access were 
improved with PD, which differed significantly with HD (Wu, 2001; Wu, 2004). 
Shrestha et al. (2008) reported better HR-QOL in PD compared to HD patients, 
especially in mental health, whereas three studies found higher depression scores 
for HD compared to CAPD patients, particularly for patients with extensive years 
of treatment (García and Calvanese, 2008; Ginieri-Coccossis et al., 2008; 
Kalender, Ozdemir, Dervisoglu & Oademir, 2007; Panagopoulou, Hardalias, 
Berati & Fourtounas, 2009). Brown (2010) found treatment modality to be an 
independent predictor of illness intrusion, particularly among patients on HD 
(higher comorbidity score) compared with PD in a cross-sectional multi-center 
study. In a US cross-sectional survey study (N=656), PD patients were more 
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likely to give excellent ratings of dialysis care than HD patients (Rubin et al., 
2004).  
In general, results for HR-QOL are not consistent when comparing PD 
with HD. A study conducted by Wu and colleagues (2004), demonstrated that PD 
was financially preferred whereas HD was preferable for sleep and overall HR-
QOL after 1 year of treatment. Based on individual preferences, HR-QOL may be 
scored better or worse. In Spain, for instance, patients reported better HR-QOL 
scores on the physical function, general health and vitality dimensions for APD 
versus CAPD, with the best scores for women in the general health dimension 
(Reina-Neyra, 2008). When PD, APD and HD modalities were compared, the best 
HR-QOL scores were noted for APD, due to patient satisfaction with treatment 
and significantly more time for work, family or social activities (Bro et al., 1999; 
Caballero-Morales, 2006; De Wit, Krediet, & De Charro, 2001).  
End-stage Renal Disease and Sleep 
The prevalence of sleep disorders in persons with ESRD is higher 
compared to the general population and negatively influences HR-QOL (Alvarez-
Ude et al., 1999; Cengić, Resić, Spasovski, Avdić & Alajbegović, 2010; Cohen, 
Patel, Peterson & Kimmel, 2007; Gusbeth-Tatomir, Boisteanu, Seica, Buga & 
Covic, 2007; Kimmel & Patel, 2006; Mei-Fen et al., 2007). Sleep disorders 
among patients with ESRD include difficulty falling asleep, nightmares, excessive 
daytime sleepiness (EDS), restless leg syndrome (RLS), sleep apnea syndrome, 
insomnia, chronic fatigue and difficulty finding a comfortable sleeping position 
(Cengić et al., 2010; Mucsi et al., 2004; Unruh et al., 2008; Yngman-Uhlin & 
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Edéll-Gustafsson, 2006).  Factors associated with sleep disturbances were 
comorbid conditions, marital status, gender (Alvarez-Ude, 1999) and cognitive 
function (Kutner, Zhang, Huang & Bliwise, 2007). In Bosnia Herzegovina, 
authors reported snoring, pain, daytime napping, and pruritus as frequent causes 
of sleep disorders. In this study, poor sleepers showed higher serum phosphate 
and parathyroid hormone, and significantly lower hemoglobin (Cengić et al., 
2010). The severity of the sleep disorder has been reported to be higher for 
patients receiving HD compared to PD (Eghbali, Shahqolian, Nazari & Babaee, 
2008), although a high rate of poor sleep quality was found in both therapies in a 
Turkish study (Eryavuz et al., 2008). 
The characteristics of some sleep disturbances in patients with ESRD may 
differ from the rest of the population. In obstructive sleep apnea (OSA), patients 
with ESRD are less likely to report snoring, witnessed apnea during sleep, 
unrefreshing sleep and morning headaches compared to normal renal function 
patients. Beecroft, Pierratos & Hanly (2009) have also reported that presentation 
of OSA‘s symptoms differ in ESRD patients from the general population. The 
sleep time of patients with ESRD is poorer with a reported 4.4 to 6 hours of sleep 
fragmented by high frequency of arousals, sleep efficiency from 66% to 85%, an 
increase in N1 (Stage 1 lightest stage of sleep) and N2 sleep (second stage of 
sleep characterized by sleep spindles and low-voltage activity) with concomitant 
reductions in N3 slow wave sleep and rapid eye movement (REM) sleep (Hanly, 
2008). Based on associations between short sleep duration with hypertension and 
type 2 diabetes (Gottieb et al., 2005, 2006), patients with ESRD could be at 
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greater risk for cardiovascular disease and mortality. A decline in sleep quality 
during the first year on dialysis has been associated with shorter survival (Unruh 
et al., 2006). Recently, it has been reported that poor sleepers receiving HD 
treatment scored worse in the physical and mental domains of HR-QOL; the 
mental component scale is a predictor for poor sleep quality (Guney et al., 2010). 
Costs-effectiveness in renal replacement therapies 
Along with the assessment of efficacy and effectiveness of a treatment and 
given the economic burden that chronic disease care represents for health care 
systems, in recent years health researchers have studied the costs (resource uses) 
and the consequences (outcomes) of alternative strategies of treatment (Virgili, 
Koleva, Garattini, Banzi & Gensini, 2010). These economic evaluations are 
highly important in such cases as renal replacement therapies when the simple 
calculation of survival and morbidity rates are no longer sufficient. Recently, the 
evaluation of the impact of the treatment on the patients‟ daily life, i.e., QOL, is 
the targeted outcome. The quality-adjusted life year (QALY) has been developed 
to include QOL and survival, i.e., „length and quality‟ of life (Wong, Howard & 
Craig, 2010). The QALY method allows the comparison of cost-utility estimates 
of different interventions for the purposes of public health decision making 
(Virgili, 2010). 
In order to calculate the QALY, researchers have to know the health state 
of the population. Utility measures in healthcare commonly used are EQ-5D and 
SF-6D, which have been developed from the EUROQOL and SF-36 instruments 
respectively, and have been called utility assessments or preference-based 
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assessments (Feeny, Wu & Eng, 2004; Hornbrook et al., 2011; Liem et al., 2008). 
The use of EQ-5D and SF-6D have shown moderate to strong correlations with 
one another and have been considered valid for application in economic health 
analysis (Goncalves-Campolina, 2010). The Health Utilities Index Mark 3 (HUI3) 
is another instrument used by researchers (Davison, Jhangri & Fenny, 2009).  
Liem and colleagues (2008) summarized the literature on health utilities in 
HD, PD and RT and compared utilities between these patients groups. They 
obtained 27 different articles which reported the use of the visual analog scale 
(VAS), time trade-off (TTO), standard gamble (SG), EuroQol (EQ-5D), and 
health utilities index (HUI). They concluded that RT patients tended to have a 
higher utility than dialysis patients. No statistically significant differences in 
utility were found among HD and PD patients. 
On the other hand, in Greece, a nationally representative sample of 
patients receiving renal replacement therapies was studied to estimate QALYs 
using the SF-6D. Results showed lifelong QALYs of 4.37 (HD), 3.94 (PD) and 
16.11 (RT). The cost per QALY differed by treatment modality; HD (€60,353) 
compared to PD (€54,504) and 1st year RT (€45,523) (Kontodimopooulos & 
Niakas, 2007). 
In Mexico, the annual costs of treating ESRD estimated by Prieto et al., 
(2007) were $24,032 USD/patient and $15,724 USD/patient for HD and PD, 
respectively. These costs included drugs, supplies, hospitalization, treatment-
related infections, infrastructure and physician and nurse fees as direct treatment-
related costs and the indirect costs related to work loss and patient transportation. 
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No QALY estimations for ESRD in Mexico were found in a search of the 
literature.  
Folk, complementary, and alternative medicine (CAM) 
Although there is no strong evidence to indicate CAM use among patients 
with ESRD  (Burrowes &Van Houten, 2005; Wojcikowski, Johnson & Gobe, 
2006) and data regarding efficacy and safety in patients with chronic disease are 
scarce, a few studies indicate that some patients with ESRD are utilizing 
supplements, herbs and other therapies given their popularity (Markell, 2005). In 
general, 18% of dialysis patients reported using some form of CAM and 63% 
reported a willingness to use CAM in a Cincinnati, Ohio survey of 153 patients 
(Duncan et al, 2006). A German study reported 57% of dialysis patients and 49% 
of transplant patients were regular CAM consumers (Nowack et al, 2009). In 
Mexico, there is a wide range of nonconventional medical practices transmitted 
over centuries by indigenous people (folk practices), or as a result of the 
acquisition of another culture‘s knowledge (alternative) that have been used 
before, during or after the practice of conventional medicine (complementary) 
(Secretaría de salud, 2007).  
Folk medicine practices are still primarily chosen by the general Mexican 
population. One of them, the ‗herbolaria‘ and two alternative therapies, 
acupuncture and homeopathy, have been recognized in the health system and their 
utilization has already been legislated (Secretaría de Salud, 2010). It has been 
suggested that when the people have access to conventional Western medicine, 
they no longer use folk and CAM practices (Van Gameren, 2010). 
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Summary 
In summary, ESRD is a chronic disease with a high global prevalence. 
Until RT is established in the health system as the first priority for treatment, 
other options should be the ones with the best clinical outcomes, lowest cost and 
the best opportunity for enhanced HR-QOL as perceived by the persons who have 
experienced the disease. There is extensive evidence of the impact of dialysis 
treatment on HR-QOL (physical, emotional, mental, spiritual dimensions) and its 
relationship to patient characteristics (age, gender, comorbidity, and marital 
status), treatment modality, other treatment-related factors and quality of care. A 
majority of these studies, however, have been done in developed countries with 
differing systems of health delivery, health care quality, dialysis therapy, cultural 
and SES factors. Few studies have been done with Latino or Mexican 
populations; therefore, findings from these prior studies are not fully 
generalizable. Furthermore, the results cannot be easily extrapolated to support 
local or national programs to improve the quality of care, design innovative 
interventions, promote the awareness of health providers, or change policy in 
Mexico. If health care innovations are going to be promoted, it is necessary to 
determine how dialysis modality and other relevant factors are associated with 
HR-QOL of Mexican persons with ESRD. 
Theoretical Underpinnings 
 The dependent variable of interest for this study is HR-QOL. Several 
nurse theorists have conceptualized QOL. Leninger, Peplau, Parse, King & 
Rogers have generally focused on the subjective perception and intangible nature 
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of the concept as the perception of one‘s lived experience (Plummer & Molzhan, 
2009; Reed & Shearer, 2009). These approaches are representative of the 
changing worldviews of health from mechanistic-reductionistic to unitary-
transformative paradigm in nursing in the US (Bernick, 2004). 
In Mexico, there has been an effort to integrate alternative modalities of 
care (Secretaría de Salud, 2007-2012). Nevertheless, in a curative model, 
conventional medical practices are still relevant and cultural beliefs could 
discourage the application of postmodern nursing theories in the clinical arena. In 
addition, language translation of conceptual theoretical components represents a 
real challenge. 
In order to avoid the classical disconnection between theory and practice, 
some concepts from Jean Watson‘s Theory of Human Caring are applied to the 
phenomenon of HR-QOL in persons with ESRD in Mexico. It is believed that 
Watson‘s theory can provide the framework for nursing care intervention for 
future studies, be understandable to administrators and raise the consciousness 
that will urge the change of paradigm needed to transform health care from the 
‗control disease, prolong life and alleviate pain‘ vision to the humanistic ‗caring 
for‘ values, quality of life and death perspective (Symonds, Berzon, Marquis, 
Rummans et al, 2002; Watson, 1981). Hence, Watson‘s (2006) theoretical 
framework will lay the groundwork for the reintegration of the caring-healing 
modalities and nursing arts to ensure attention to quality of life, inner healing 
experiences, subjective meaning, and caring practices that will affect patient 
21 
outcomes and system successes alike. Quality of life and other related features of 
persons with ESRD are consonant with this theoretical model. 
 In agreement with Watson (1999), attending the person as a total being is 
more than cure and physical treatment of diseases, especially for a person with a 
chronic condition and end-of-life challenges.  The caring-healing focus ―draws 
attention to the unique human qualities that are embedded in each individual and 
upholds the ethical and moral value of care that informs the praxis of caring 
within the nursing discipline‖ (Bernick, 2004). Findings from this study will 
provide the basis for understanding the Mexican ESRD patient‘s perception of 
his/her HR-QOL, and will offer practice reflections (Watson, 2006, p.50), 
including : 
• Human caring is not a commodity to be bought and sold; and 
• Caring and economics are not mutuality exclusive, and can co-exist to achieve 
cost-benefits and cost-effectiveness. 
 Potential theory-based nursing interventions would utilize several of the 
―carative‖  factors proposed by Watson (1988) to help nurses with their human 
activity, including  ‗sensitivity to self and to others,‘ ‗expressing positive and 
negative feelings,‘ ‗creative problem-solving,‘ ‗caring processes,‘ ‗human needs 
assistance‘ and ‗supportive, protective, and/or corrective mental, physical, 
societal, and spiritual environment.‘ Laying the groundwork for the reintegration 
of the caring-healing modalities and nursing arts to ensure attention to QOL, inner 
healing experiences, subjective meaning, and caring practices will combine to 
promote positive patient outcomes and system successes alike (Watson, 2006).  
22 
Chapter 3 
RESEARCH DESIGN AND METHODS 
Design 
Because few previous data were found regarding the HR-QOL of Mexican 
patients with ESRD, this is a descriptive, exploratory, cross-sectional study. This 
pilot project was designed to provide information for future quasi-experimental 
and experimental studies examining the effects of an evidence-based, theory-
based nursing intervention to improve the HR-QOL and sleep disorders among 
persons with ESRD in Guanajuato, Mexico. 
Sampling Method 
As described above, there are three kinds of healthcare institutions in 
Mexico. To eliminate bias, patients were selected from one type of insurance 
(ISSSTE), and they were proportionately selected by clusters. A convenience 
sample included 30 patients from each geographic location of dialysis treatment 
units in Guanajuato State (the cities of Celaya, Irapuato, Guanajuato and Leon); 
ten patients were selected per each dialysis modality (Continuous Ambulatory 
Peritoneal Dialysis [CAPD], Automated Peritoneal Dialysis [APD], and 
Hemodialysis [HD]).  
Persons with dialysis treatment in each unit were invited to participate in 
the study either during their monthly meetings or in the waiting room for their 
specialist appointment. They received general information about the project, and 
if they were interested in participating, they were asked to give their contact data 
to researchers, and make an appointment. Most of the time, the patient agreed to 
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be interviewed at that moment. The total number of potential participants to be 
recruited was 125. The study was approved by the University of Guanajuato 
Ethics Committee and the Arizona State University Institutional Review Board. 
Participants 
During the appointment with the research team member, the participant 
was asked to provide written informed consent and to complete an individual 
interview/survey about their health, health and folk practices, sleep, HR-QOL, 
spirituality, anxiety, and depression. They were also asked to give consent for 
chart review (Appendix A). 
Inclusion criteria: Patients who were 18 years old or older, attending the 
ISSSTE and receiving dialysis treatment for ≥6 months were eligible. The 
minimum 6 months of dialysis criteria ensured that all patients had completed the 
initial process of adaptation. Participants had to be Spanish-speaking volunteers 
capable of providing written informed consent and with no hospitalizations during 
the past three months of the interview. These criteria ensured that HR-QOL would 
be directly attributed to daily living with ESRD treatment, rather than 
complications from an acute illness or current hospitalizations. Participants were 
enrolled in the study without regard to gender, ethnicity, or educational 
achievement.  
Exclusion criteria: Patients with cognitive or other mental health deficits 
that would preclude them from completing survey questionnaires were excluded 
from the study.  
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Setting 
The interview was held in a private room in the dialysis unit of the clinic, 
or at the patient‟s home depending on each patient‟s preference. The first part of 
the interview consisted of questions regarding demographics and medical history. 
The interview also asked questions about complementary traditional and 
alternative medicine practices, sleep disturbances, HR-QOL, spiritual perspective, 
depression and anxiety (Appendix B1 English and B2 Spanish). 
Procedure 
Recruitment and Enrollment. Figure 3 illustrates the study flow chart. 
The Medical Director of each clinic was asked to give the authorization to the 
research team to visit each clinic. Only one director returned written acceptance 
(Appendix C). Once the visit to the clinic was accepted by the administration, 
information about the project was given to the dialysis nurse manager related to 
the purpose of the study, the inclusion/exclusion criteria and the risks of the study 
for the potential participants. Interested potential participants were screened to 
confirm that they met the inclusion criteria and, if so, the researcher provided and 
explained the informed consent document. The participant or the companion was 
asked to provide contact information and schedule the interview with the research 
team. The majority of the time, the patient agreed to be interviewed, either before 
or after the medical appointment. 
Informed Consent. The principal researcher explained the purpose of the 
study, risks and benefits, and the time needed to participate in the interview. 
Patients were informed that participation was completely voluntary and that non- 
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participation would not affect their healthcare. They were asked to sign an 
informed consent only after they were fully informed and able to indicate their 
understanding of the study. Participants were asked to provide written consent for 
the release of information from medical records (Appendix A). 
 Data Collection. Research assistants included one nursing student and one 
licensed nurse. They were trained regarding the project aims, interviewing 
techniques, and use of the instruments one month prior to the start of the data 
collection. They were provided with all the materials needed for the interviews, 
and financial support for travel and food expenses. The principal investigator also 
carried out interviews.  
The interviewers obtained information regarding age, gender, marital 
status, SES, educational level, number of hospitalizations, time since first 
treatment, and CAM/folk use. Participants also completed the Spanish translated 
and validated Sleep Heart Health Study (SHHS) Sleep Habits Questionnaire 
(SHQ), the Spanish version of the 36-item Medical Outcomes Study (MOS) short 
form (SF-36) HR-QOL measure, the Latino Spirituality Perspective Scale, and the 
Hospital Anxiety and Depression Scale (HADS). Height and weight were 
obtained to determine body mass index (BMI). Recent glucose, albumin, 
creatinine, urea, and hematocrit/hemoglobin blood levels were extracted from the 
patient‟s medical record within the past three months. Additional clinical data 
collected to calculate the financial cost were ESRD etiology, hospitalizations 
within the past year, type of catheter, dialysis dose, number of anti-hypertensive 
drugs, use of erythropoietin, number of HD sessions per week and last home visit 
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by the dialysis team. In order to determine quality adjusted life years (QALYs), 
type and time of dialysis were collected and examined with respect to SF-6D 
utility index scores. 
Measurement Tools 
Sleep Heart Health Study Sleep Habits Questionnaire. See Table 1 for 
the full listing of measures used in this study. The SHQ instrument typically has 
been used with patients with unidentified sleep disorders. The questionnaire 
addresses ten aspects of sleep disorders: 1) Snoring, which is ascertained by the 
question "Have you ever snored (now or at any time in the past)?" with possible 
responses "yes," "no," or "don't know." Participants answering "yes" were asked, 
"How often do you snore now?" with possible responses including "rarely--less 
than one night a week," "sometimes--1 or 2 nights a week,‖ "frequently--3 to 5 
nights a week," "always or almost always--6 or 7 nights a week," or "don't know;"   
2) Breathing pauses (apnea) were ascertained by the questions, "Are there times 
when you stop breathing during sleep?" and ―Has anyone ever told you that you 
stop breathing during sleep?‖ with possible responses "yes," "no," or "don't 
know;" 3) Witnessed apneas were assessed with participant response to a question 
as to how often there is someone else nearby while they are sleeping, with 
possible responses of "never," "sometimes," and "always;" 4) Daytime sleepiness 
from two somnolence statements, "Feel excessively (overly) sleepy during the 
day,‖ and "Feel unrested during the day, no matter how many hours of sleep you 
had;" 5) Insufficient sleep with the question "Not getting enough sleep;" 6) 
Insomnia symptoms with the statements "Trouble falling asleep," "Wake up 
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during the night and have difficulty resuming sleep," and "Wake up too early in 
the morning and be unable to resume sleep;" 7) Nightmares, 8) Restless legs 
syndrome (RLS) using questions regarding leg sensations, time of day, alleviation 
of symptoms, family history; and 9) Self-reported weekday and weekend sleep 
duration. Sleep symptoms questions were rated on a 5-point Likert-type scale 
from ‗Never‘ to ‗Almost Always.‘  
The SHQ examined by Kump and colleagues (1994) was shown to have 
validity for characterizing symptom distributions in an epidemiological study of 
sleep. Sleep habits, sleepiness and daytime performance from 465 participants 
were analyzed with factor analysis, logistic regression, and receiver-operator 
characteristics (ROC) with area under the curve (AUC) estimates. Subscales 
demonstrated excellent internal consistency (Cronbach‘s alpha: 0.91 to 0.98). 
Analysis identified five factors: 1) functional impact of sleepiness, 2) self-
reported breathing disturbances; 3) witnessed apnea, 4) insomnia symptoms, and 
5) driving impairment. Logistic regression demonstrated that OSA-associated 
apnea could best be predicted by three questions about snoring intensity, 
witnessed apnea, and falling asleep while driving (ROC AUC: 0.78). Adding the 
variables gender and BMI improved predictive ability by 10% (ROC AUC: 0.87) 
(Kump et al., 1994). The questionnaire has been used in a variety of investigations 
since that time as well as with over 6400 subjects in the SHHS and is generally 
accepted as an appropriate means of characterizing sleep health (Baldwin et al., 
2010, 2001; Baldwin, Kapur, Holberg, Rosen & Nieto, 2004; Gottlieb et al., 2005; 
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Gottlieb et al., 2006; Newman et al., 2001; Nieto et al., 2000; O‘Connor et al., 
2002; Resnick, Redline, Shahar, Gilpin et al., 2003; Winkelman et al., 2008). 
The Spanish version of the SHQ was cross-language validated by Baldwin 
and colleagues (Baldwin et al., 2008; Baldwin et al., 2009); translations and back-
translations were performed and the English and Spanish SHQs were completed 
by bilingual participants one week apart in randomized fashion. The sample was 
52% women and 92% Hispanic, primarily of Mexican heritage. Mean age was 39 
years (SD=12) and mean education was 15 years (SD=3). Psychometrics for the 
English version of the SHQ showed a Cronbach‘s alpha of 0.82 for the 12-item 
sleep symptoms (e.g., daytime sleepiness, insufficient sleep and leg jerks) and 
0.71 for the 3-item insomnia symptoms (have trouble falling sleep, staying asleep, 
wake up too early in the morning and unable to return to sleep). For the Spanish 
version, the Cronbach‘s alpha was 0.85 for 12-item sleep symptoms and 0.81 for 
3-item insomnia symptoms. Spearman-Brown correlations were > 0.90 for all 
sleep categories, suggesting strong agreement between language versions. 
Correlation and agreement between the Spanish and English versions of 
the 3-item insomnia symptoms category was also analyzed by Baldwin and 
colleagues (2009) in the cross-language validation study. Total and category 
scores for the insomnia symptoms were compared across Spanish and English 
versions for subgroups defined by order of assessment, gender, age, education, 
language facility, acculturation, or health condition. English and Spanish versions 
were highly correlated with r values ranging from 0.83 to 0.94. Classification 
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congruence for insomnia symptoms was also good with Φ and κ ranging from 
0.63 to 0.79. 
Epworth Sleepiness Scale. The Epworth Sleepiness Scale (ESS) is a 
validated self-completion tool that asks subjects to rate the likelihood of falling 
asleep in several common situations (Johns, 1991). The ESS was assessed by the 
question, "What is the chance that you would doze off or fall asleep" followed by 
a list of eight common situations including "riding as a passenger in a car," 
"watching TV," and others. For each situation, possible responses include four 
ordinal categories ranging from 0 (no chance) to 3 (high chance). Scores range 
from 0 to 24 with a score of >10 suggesting EDS (Gottlieb et al., 2005). The 
Epworth was included with the SHQ in the Spanish translation and validation 
study. Cronbach‘s alphas for the English and Spanish versions were 0.83 and 0.81 
respectively. Spearman-Brown correlations were >0.90 for both language versions 
(Baldwin et al., 2008, 2009).  
CAM practices instrument. The 2007 National Health Interview Survey 
(NHIS) Questionnaire survey of adult health, complementary and alternative 
medicine (CAM) was adapted for this study. This questionnaire was part of a 
multi-purpose health survey conducted by the National Center for Health 
Statistics (NCHS, 2007), Centers for Disease Control and Prevention, and is the 
principal source of information on health of the civilian, non-institutionalized 
household population of the United States. The Adult CAM Supplement was 
designed to collect information from adults on their use of 18 non-conventional 
health care practices, including acupuncture, ayurveda, biofeedback, chelation 
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therapy, chiropractic or osteopathic manipulation, energy healing therapy, 
hypnosis, massage, naturopathy, traditional healers, movement therapies, herbal 
and non-vitamin supplements, vitamins and minerals, homeopathy, special diets, 
yoga/tai chi/qi-gong, relaxation techniques, and prayer for health reasons. 
Questions were asked about use, frequency, and cost of the eighteen different 
practices, conditions for which the modality was used, for which health 
conditions, treatment received and whether they told their primary care providers 
about their CAM use. In addition to these modalities, Mexican folk practices for 
self-treatment of ESRD, including herbal remedies, use of a sobador or 
curandero, or other non-Western medicine practice not listed on the NCHS 
survey were included to assess for traditional Mexican culture care. 
Latino Spiritual Perspective Scale (LSPS). This questionnaire assesses 
spiritual beliefs, feelings, and practices among Latino populations. Reliability 
testing showed a Cronbach‟s alpha range of 0.88-0.93 in US English speaking 
samples of adults, and 0.93 for the Spanish version in a sample of bilingual adults 
(Campesino & Schwartz, 2006; Campesino, Belyea & Schwartz, 2009). Eight 
items from the spirituality scale validated by Campesino and colleagues (2009) 
were used to examine spirituality of the Mexican participants with ESRD. The 
statements were rated by the patient on a Likert-type scale from 6 (strongly agree) 
to 1 (strongly disagree). Two additional questions were ranked on a 5-point scale 
from 0 (not or no) to 4 (extremely) to determine the degree to which participants 
conceptualized themselves as spiritual persons and the degree to which their 
spirituality or religion helped to endure their chronic disease. A third question had 
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the participants indicate the frequency with which they performed spiritual or 
religious activities, including prayer, meditation or attending religious activities 
on a scale of 0 (never) to 3 (daily).  
Hospital Anxiety and Depression Scale (HADS). The HADS was 
developed by Zigmond and Snaith (1983) for use with physically ill patients. 
Numerous studies worldwide have reported clinically meaningful results with 
several aspects of disease and QOL (Herrmann, 1997). The depression scale 
consists of 7 items (e.g., loss of interest, feeling slowed down) scored from 0 to 3 
with a range of 0 (low) to 21 (high) probability of depression. The anxiety scale 
consists of questions relevant to worry, tension and fear and is scored in the same 
manner as the depression scale. The authors suggested that a score above 8 on an 
individual (depression or anxiety) scale should be regarded as a possible case and 
a score above 10 as a probable case of depression or anxiety. Tyrer and Methuen 
referred to the HADS as the third most commonly used self-report screening 
instrument; the citation rate per year has been reported to be 1,333 (Brennan, 
Worral-Davies, McMillan, Gilbody & House, 2010). 
According with Brennan and colleagues (2010) this instrument has been 
shown to be a useful screening tool for identifying emotional distress in non-
psychiatric patients. They conducted a meta-analysis and found that for major 
depressive disorders, a cut point of  ≥ 8 gave a sensitivity of 0.82 (95% CI, 0.73–
0.89) and a specificity of 0.74 (95% CI, 0.60–0.84) and a cut point of ≥ 11 gave a 
sensitivity of 0.56 (95% CI, 0.40–0.71) and a specificity of 0.92 (95% CI, 0.79–
0.97). The HADS has been published by Granada Learning Assessment Limited, 
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part of the Granada Learning Group, and a license to use it was properly 
purchased (Appendix E). 
Medical Outcomes Survey (MOS) Short Form SF-36 (Spanish 
version). The MOS SF-36 measures variations in health care practices and 
outcomes in a self-administered survey that assesses eight health dimensions. 
Scores for each subscale range from 0–100, with higher scores representing better 
quality of life (Ware et al., 1992). Subscales measure the following eight general 
health concepts: physical activities (PF), role physical (RP), bodily pain (BP), 
general health (GH), vitality (VT), social functioning (SF), mental health (MH) 
and role emotional (RE) (McHorney, Ware and Raczec, 1993; McHorney, Ware, 
Rachel Lu & Sherbourne, 1994). Some of the scales (PF, GH, VT, and MH) are 
heterogeneous in terms of item content. The median item-scale correlation 
(corrected for overlap) for each of the eight scales was very high, ranging from a 
low of 0.63 (GH) to a high of 0.79 (MH).  When testing for internal consistency, 
the 0.40 standard was achieved 97% of the time. Internal-consistency reliability 
coefficients for each of the scales exceeded the minimum reliability standard of 
0.50 to 0.70 recommended for group comparisons. The SF-36 survey also 
includes a single-item measure of health transition, which is not used to score any 
of the eight multi-item scales (McHorney, 1994). The SF-36 questionnaire is a 
widely-used measure of health status and health-related quality of life (HR-QOL) 
with a substantial body of evidence supporting its reliability and validity in a 
variety of patient populations (Baldwin et al., 2001, 2010; Bennett & Riegel, 
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2003; Kung & Lu, 2008; Laureau, Breslin & Meek, 1996; Stewart, Hays & Ware, 
1988; Ware, Snow, Kosinski & Gandek, 1993). 
Short Form-6 D scores. The SF-6D is a preference-based health state 
classification developed from the SF-36. All participants who complete the SF-36 
can be assigned an SF-6D score (Brazier, Roberts & Deverill, 2002). The SF-6D 
is a continuous measure, scored on a 0 (death) to 1 (optimal health) scale. Cost 
effectiveness and impact studies using the SF-6D have examined health state 
utilities and diabetes prevention, and predictors of SF-6D scores of persons with 
colorectal cancer (Ackermann et al., 2009; Hornbrook et al., 2011). 
Cost assessment. Cost by type of ESRD treatment for CAPD and APD 
was obtained from the Sub-direction of Regulation and Hospital Attention of the 
Medical Direction of the ISSSTE online report for contracted services from 2010 
to 2011 (Delgado-Serrano, 2011). The cost for each dialysis type included tubing, 
solution, mini-cap for line closing (four mini-caps per day), APD machine 
maintenance, home delivery, first-time catheter and connector and new transfer 
line every six months.  Both CAPD and APD were done at home. The cost for 
CAPD and APD does not include taxes, catheter insertion costs, physician or 
nursing fees, monthly visits to the nephrology clinic or patient/primary caregiver 
training, transportation, home visits, or medication. 
The cost for HD was obtained from the online publication of the contract 
that the ISSSTE made for the HD services for 2010 to 2012 (Contraloría 
Ciudadana para la Rendición de Cuentas, A.C., 2010). Cost for HD included all of 
the solution, lines, machinery, water treatment for the dialysis machines required 
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for each session. The cost for HD did not include taxes, cost for vascular access, 
tri-weekly transportation to and from the clinic, clinic costs, nephrology visits, 
nursing care, patient/primary caregiver education or medications. Each modality 
cost was calculated based on average number of treatments relevant to the 
modality type. Costs for each dialysis modality were estimated for one year.  
Ethics and Human Subjects 
This research was consistent with the Mexican “Ley General de Salud,” 
which regulates the Mexican health system. This research was approved as 
fulfilling the ethical guidelines as outlined in the Human Subjects section titled 
“Investigación para la Salud,” and the study was found to be of minimal risk for 
participants. This study was approved minimal risk to the participants. Following 
the Helsinki Code, participants signed a consent form, and were assured that their 
participation was completely voluntary and could be terminated at anytime 
without compromising their medical care. The University of Guanajuato approved 
the protocol by the university ethics committee (see Appendix D-1). The study 
was protocol was approved by the Arizona State University Institutional Review 
Board (Protocol Number 1104006292) (See Appendix D-2). 
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Chapter 4 
DATA ANALYSIS AND RESULTS 
Data Analysis 
 Descriptive analyses were performed for all variables. Continuous 
variables are reported as means and standard deviations and categorical variables 
by percentages. A chi-square test was used to assess the association of 
demographic characteristics with dialysis modality. Comparisons between HR-
QOL scores and the treatment groups were performed by analysis of variance 
(ANOVA). Multiple linear regression analysis was performed controlling for 
demographics, income (SES), sleep disorders, spirituality, and CAM variables. 
The significance level of p<0.10 was adopted because this is a pilot study with 
three groups and a small sample size. SAS software (V9.1) was used for data 
analysis. 
The cost analysis utilized the quality-adjusted life year (QALY) method to 
investigate the cost-effectiveness of each dialysis modality group. The QALY was 
computed as the number of years on dialysis/hemodialysis time SF-6D score. A 
ratio of the difference in cost to the difference in effectiveness (QALY) was 
computed for each of the three therapies which yielded the incremental cost-
effectiveness ratio (ICER). 
Population 
The study population was recruited from the four ISSSTE clinical 
hospitals in Guanajuato State (Celaya, Irapuato, Guanajuato and Leon cities). 
There were 125 patients at the beginning of the study, two patients never started 
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the study because they were less than 18 years old, one patient interrupted the 
interview and was hospitalized after a medical appointment, and one patient did 
not finish the interview and was eliminated. One-hundred and twenty-one patients 
fulfilled the inclusion criteria and all agreed to voluntarily participate and 
provided written informed consent. Table 2 shows city of origin and dialysis 
modality of the population included in the study.   
Aim 1. To characterize the demographics, socioeconomic status (SES), health 
histories, prevalence rates and types of sleep disorders, folk practices used, 
spiritual perspective, anxiety, depression, and HR-QOL scores of Mexicans 
with ESRD for each of 3 types of dialysis. 
Overall, ESRD patients had an average age of 59 (SD=13) years, were 
predominantly men (55.4%), married (66.9 %), Catholic (92.6%), and not 
currently working (78.3%). Overall, 57% of participants reported a yearly income 
of less than $4,823 USD. The average number of people in living in the household 
was 4; interestingly, 48.8 % and 54.1% of all participants reported have never 
smoked or consumed alcohol, respectively. 
The distribution for dialysis type was CAPD (n=39), APD (n=42), and HD 
(n=40). Demographic characteristics for each dialysis modality group are 
compared in Table 3. Patients on APD compared to CAPD and HD were younger 
(53 years versus 64 and 61 years respectively, p=0.0001), had more education (11 
years versus 8 and 9 years respectively, p =0.06), more likely to be employed 
(33% versus 5% and 8% respectively, p=0.002), and had incomes in the $4K to 
$6K range (21% versus 10% each, p=0.05). Notably, however, the patients on 
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APD also showed extremes in income. For example, 24% of the APD group 
reported no annual income compared to the CAPD and HD groups (18% and 10% 
respectively, p=0.05), while both the APD (26%) and CAPD (26%) groups 
reported incomes in the  >$8K range compared to the HD group (15%, p=0.05). 
The APD patients were significantly more likely to report a past history of alcohol 
intake (63%) compared to the CAPD and HD groups (31% and 41% respectively, 
p=0.04). None of the groups reported current alcohol use. The treatment groups 
did not differ significantly with respect to gender, marital status, smoking, 
religion, medical insurance, years of education, or number of people in the 
household. 
The majority of the subjects were diabetic (72%) and slightly overweight 
(BMI: M=26.1, SD=5.1). Participants took an average of 6 medications daily 
including erythropoietin (90%) and reported a mean systolic blood pressure (SBP) 
of 144 (SD=27) and mean diastolic blood pressure (DBP) of 80 (SD=17). Thirty-
three percent reported taking more than two different antihypertensive 
medications. In general, the study population reported at least three comorbidities, 
including diabetes and ESRD. Forty-seven percent have not been hospitalized 
during the prior 12 months and 25% had been hospitalized for less than three 
days. Laboratory data registries were as follows, mean hemoglobin=11.2 (SD=3 
g/dl), mean albumin=3.5 (SD=0.7 g/dl), mean urea=96.4 (SD=39 mg/dl), mean 
creatinine= 9 (SD=4.3 mg/dl), mean BUN=49 (SD=18 mg/dl), and mean 
glucose=123 (SD=53 mg/dl). 
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  CAPD patients tended to be older (M=64.2, SD=8.9, p=0.000), not 
working (92.1%, p=0.002), had higher BMI (M=27.7, SD=5.6, p=0.06), SBP 
(M=147.7, SD=31.7) and glucose levels (M=129.1, SD=5.4) and reported taking 
more medications (M=6.8, SD=2.6). APD patients tended to be younger (M=53.1, 
SD=13.4, p=0.000), married (66.7%), working (33%, p=0.002), more educated 
(M=11.4 years, SD=6.4, p=0.06), had a higher annual income (26.2%, p=0.05), 
had an elevated DBP (M=84.9, SD=14.1), higher creatinine (M=11.8, SD=4.3, 
p=0.00) and urea levels (M=102, SD=39.3) and fewer hospitalizations in the past 
year (78.6%, 0-1 times). HD patients had higher albumin levels (M=3.9, SD=0.5, 
p=0.002), took fewer antihypertensive medications (35.9%), had lower BMI 
(M=24.8, SD=5.4, p=0.06) and more use of erythropoietin (100%, p=0.06). Both 
PD (CAPD and APD included) and HD patients had a mean time in the therapy of 
26 months. The remaining clinical characteristics are presented in Tables 4 and 5. 
Sleep Disorders. An overview of sleep disorders by dialysis type are 
provided in Table 6. Notably, all patients reported at least one sleep symptom in 
the past year. Patients on APD (21%) were significantly less likely to report un-
refreshing (non-restorative) sleep compared to the CAPD (41%) and HD (43%, 
p=0.08) groups. Insomnia was most frequently reported for patients receiving HD. 
Interestingly, HD patients reported higher rates of non-restorative (un-refreshing) 
sleep (43%), insufficient sleep (30%) and tiredness during the day (23%) on the 
SHQ compared to the patients on other therapies. Alternatively, APD patients 
reported higher rates of snoring (26%, p=0.07) and witnessed apneas (14%, 
p=0.04). CAPD (26%) and HD (25%) patients reported higher rates of EDS on 
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the Epworth scale compared to APD (13%) patients. The CAPD patients also 
reported higher rates of RLS (23%) compared to patients on HD (18%) and APD 
(17%), but had lower rates of insufficient sleep (26%) than APD (28%) and HD 
(30%) patients. Patients receiving APD were less likely to report EDS on the 
Epworth (12%), feeling excessively tired during the day on the SHQ (19%), RLS 
(17%) and insomnia (31%) compared to patients on CAPD and HD. These 
differences, however, were not statistically significant between groups for sleep 
variables other than un-refreshing sleep, snoring and witnessed apnea.  
Anxiety and Depression. The assessment of anxiety and depression based 
on the HADS showed scores within normal levels in the study population for 
anxiety (M=5.4, SD=5.2) and depression (M=5.5, SD=4.8) (see Table 7). Mean 
scores for anxiety were lowest (less anxiety) for HD (M=3.8, SD=3.9), higher for 
APD (M=5.1, SD=5.2) and highest for CAPD (M=7.3, SD=6.0, p=0.03) patients. 
Scores for the CAPD patients suggest borderline anxiety. As well, mean scores 
for depression were lowest for HD (M=3.8, SD=2.9), then APD (M=6.2, SD=5.2) 
and CAPD (M=6.5, SD=5.6, p=0.05) patients.  
Prevalence of abnormal anxiety across the three groups is 18.7% with the 
highest rates of abnormal anxiety among CAPD (24%), then APD (22%), then 
HD (10%) patients. The rates within the borderline range for anxiety are similar 
with CAPD patients reporting highest levels of anxiety and HD patients reporting 
lowest levels. Alternatively, HD patients show greater representation in the 
normal range (87%), then APD (72%) and the lowest percentage among the 
CAPD (62%) patients. Overall, the rates for anxiety within each of the levels by 
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group is significant (p=0.06). The prevalence of abnormal depression levels is 
11% with CAPD and APD groups showing equivalent rates (17% and 16% 
respectively).  Interestingly, APD patients show the highest prevalence for 
borderline depression (19%) compared to CAPD and HD patients (each 10%).  
Rates within the normal range are highest for HD (90%), then CAPD (72%), then 
APD (66%) patients. On the whole, rates for depression within each of the levels 
by modality are significant (p=0.045).   
CAM use. Overall, twenty-five patients (21%) stated that they had used 
some form of CAM. The proportion of lifetime CAM use was similar across all 
dialysis modalities. Eighteen of 121 patients (15%) indicated that they used CAM 
during the past 12 months, again with very similar proportions across all dialysis 
modalities. Seventy-three percent of the sample reported that ESRD led to CAM 
use and 77% reported that CAM was effective. The most frequently reported 
types of CAM were homeopathy (4%), herbal preparations (3%), acupuncture 
(2%), massage (2%) and vitamins (2%). When questioned about self-medication 
(allopathic, CAM, or folk), 15% of the participants confirmed the use of 
medications for headache (55%), flu (16.7%), and debilitation (11%). 
Spirituality. Participants, in general, agreed with the spiritual beliefs and 
practices stated in the LSPS (M=5.5, SD=0.7). The CAPD patients showed a 
tendency to report ―strongly agree‖ (M=5.7, SD=0.05) to the LSPS spirituality 
questions, although no significant differences were observed between groups for 
any items. Approximately 47% of participants considered themselves to be 
spiritual persons, while 48% reported frequent use of or participant in 
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spiritual/religious practices, and 72% indicated that these practices were used to 
help cope with their disease (Table 8). The HD group was most likely to consider 
themselves to be spiritual (61%) compared to CAPD (54%), then APD patients 
(30%, p=0.06). The CAPD patients were more likely to report the use of 
spiritual/religious practices (62%), then HD (52%), then APD (33%) patients. Use 
of these practices to help endure their disease was highest among HD (83%), then 
CAPD (73%), then APD (63%) patients. The findings for spiritual/practices, or 
their use for disease were not significant at the p<0.10 level. 
HR-QOL. Table 9 and Figure 5 present the comparison of the eight SF-36 
domains and the Physical and Mental Component Summary (PCS and MCS) 
scores for the three dialysis modality groups.  The patients on HD reported 
significantly better HR-QOL on the Vitality (p<0.05) and Social Functioning 
(p<0.01) scales compared to the patients on CAPD and APD; however, the CAPD 
patients reported the poorest quality of life on these two scales compared to the 
other two groups. The APD and HD patients reported significantly better Physical 
Functioning and Role Physical HR-QOL compared to the CAPD patients (each p 
<0.10). There were no significant differences between groups for Bodily Pain, 
General Health, Role Emotional and the Mental Health domains. The patients on 
HD and APD reported significantly better mental health on the MCS compared to 
patients on CAPD (p=0.07); however, there were no significant differences 
between groups for physical health on the PCS. The SF-6D score, derived from 
the SF-36, indicates the level of health and wellness on a 0 (dead) to 1 (best 
health) scale. The SF-6D score, a measure of health utility, is used in cost analysis 
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and complement the HR-QOL findings. The CAPD group showed significantly 
poorer SF-6D health utility (0.59) compared to the HD and APD patients (0.68 
and 0.69 respectively, p<0.01). 
 Table 10 displays the SF-36 and MCS and PCS scores for comparison 
between the patients with ESRD in this study, the Mexican General Population 
Norms (Durán-Arenas, Gallegos-Carrillo, Salinas-Escudero, & Martínez-Salgado, 
2004) the US General Population Norms and US Norms for Persons with 
Hypertension, Type 2 Diabetes and Congestive Heart Failure (CHF) (Ware, 
Kosinski, & Keller, 1994; Ware, Snow, Kosinski, & Gandek, 1997). Norms for 
hypertension and diabetes are included given their relationships with ESRD, and 
CHF is included as it is akin to HR-QOL debilitation noted among persons with 
ESRD. Notably, the SF-36 scores for the Mexican patients with ESRD are lower 
(suggesting poorer HR-QOL) for the eight scale and composite scores compared 
to the Mexican general population norms (Duran-Arenas et al., 2004) and similar 
to the US norms for persons with CHF (Ware et al., 1994, 1997). There are no 
extant SF-36 or PCS and MCS norms for persons with ESRD in Mexico or in the 
United States. 
Aim 2. To analyze HR-QOL outcomes of Mexicans with ESRD on 3 
modalities of dialysis controlling for demographics, SES, sleep disorder 
types, spiritual perspectives, and folk practices used. 
 The overall model accounted for 31% of the variance in HR-QOL which 
was highly significant (F=3.36, p=.002). After controlling for demographics (age, 
sex, and comorbidities), SES (income as proxy), sleep disorders, spirituality, and 
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CAM use, there were statistically significant differences in HR-QOL by dialysis 
type (Table 11). Income, sleep disorders, and comorbidities were significant 
predictors of HR-QOL. The CAPD group demonstrated significantly lower HR-
QOL scores (M=.56, SE=.03) compared to the APD group (M=.68, SE=.03, 
p=.009) and the HD group (M=.64, SE=.03, p=.08).   
 The same model was repeated with the PCS (Table 12) and MCS (Table 
13) scores as dependent variables. The PCS model was not statistically significant 
and no differences in PCS scores were observed by dialysis group. The MCS 
model (Table 13) accounted for 34% of the variance (F=4.02, p=.0004). Sleep 
disorders (p<0.001) and income (p<0.05) were the only significant covariates and 
there were statistically significant differences in MCS scores by dialysis group 
(F=4.87, p=0.01). Similar to what was observed for HR-QOL, the CAPD group 
demonstrated significantly lower MCS scores (M=42.99, SE=2.49) compared to 
the APD group (M=52.20, SE=2.32, p=0.01 and the HD group (M=51.35, 
SE=2.58, p=0.02). 
Aim 3.  To examine associations between cost effectiveness and dialysis 
modalities among Mexicans with ESRD.  
Total hospital costs for each dialysis type were obtained. The QALY was 
computed as the number of years on dialysis/hemodialysis x SF6-D score (SF-6D 
scores are presented in Table 9). The incremental cost-effectiveness ratio (ICER) 
is calculated as a cost/QALY. The results of these analyses (Table 14) 
demonstrate that based solely on hospital costs, APD is the preferred dialysis 
type. Although CAPD was the least costly alternative, it was the least effective, 
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thus it was inferior to APD and HD. Comparing the ICER for APD and CAPD, 
only $239 needs to be spent for APD to gain an additional QALY. Examination of 
the ICER for HD versus CAPD revealed that HD is the preferred strategy because 
the cost/QALY is only $759. The analysis compared the two preferred strategies. 
APD was superior to HD because it was less costly and more effective.  
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Chapter 5 
DISCUSSION 
 Traditionally, medical professionals focused on extending survival rates 
for persons with ESRD. In the past two decades, HR-QOL has become an 
important treatment goal and outcome measure for patients with ESRD (Anderson 
& Burckhardt, 1999; Harris, et al., 2002). To date, however, there are few studies 
that have provided HR-QOL norms or guidelines for patients being treated for 
ESRD in Mexico. This study extends the literature in several ways: 1) Findings 
provide SF-36 and PCS and MCS scores as a basis for norms for Mexican patients 
with ESRD on three distinct types of dialysis (APD, CAPD and HD); 2) The HR-
QOL norms provide the basis on which treatment outcomes can be evaluated; 3) 
Sleep disorders have been identified as significantly associated critical factors that 
contribute to poorer mental HR-QOL of Mexican patients with ESRD; and 4) cost 
comparisons of the two leading dialysis types indicated that APD was superior to 
HD due to reduced cost and improved outcomes, which can inform health policy 
and treatment for Mexican patients with ESRD.  Furthermore, comparisons of 
norms for the Mexican General Population, the US General Population, the 
Mexican patients with ESRD, and US patient with hypertension, type 2 diabetes 
and CHF are also available (Table 10) are presented for bi-national evaluation.   
HR-QOL and Dialysis Modality. In Mexico, estimates suggest that there 
are approximately 100,000 patients with ESRD of which 80% are on CAPD (least 
expensive and poorest HR-QOL in this study), 19% are on HD (most expensive 
with HR-QOL comparable to APD in this study), and 1% are on APD (HR-QOL 
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comparable to HD in this study at reduced cost) (Fundación Mexicana del Riñón, 
2007). The present research is one of the few studies that compared patients‟ 
perceptions of HR-QOL among dialysis modalities (CAPD, APD and HD) in 
addition to other lifestyle factors that may be influenced by a history of ESRD and 
ultimately further compromise HR-QOL. Caballero-Morales & colleagues (2006) 
reported better HR-QOL in most of the SF-36 domains for APD versus CAPD 
and HD patients; notably, their HD patients reported the poorest HR-QOL, while 
the HR-QOL of the HD and APD patients in this study were comparable. 
Differences among patients on HD in this study could be explained by factors that 
include advanced training of medical and nursing personal in HD units, greater 
participation of nephrologists in medical management, and the extensive 
availability of HD as a treatment option contributing to APD and CAPD as less 
likely treatment options.  
Interestingly, in prior international studies, no significant differences were 
reported between PD and HD patients‟ overall HR-QOL (Mau, 2008; Morales-
Jaimes, 2008; Peng, 2010; Wasserfallen, 2004). However, some authors have 
reported significantly higher scores in SF-36 domains, including Physical and 
Social Function, Bodily Pain, Vitality, Role Emotional and the MCS among PD 
compared to HD patients (Brown, 2010, Caballero.Morales, 2006, Frimat, 2006; 
Fructuoso, 2011; Ginieri-Coccossis, 2008; Harris, 2002; Juergensen, 2006, 
Kalender, 2007; Kutner, 2005, Liem, 2007; Mittal, 2001; Peng, 2010; Shrestha, 
2008; Wu, 2004). A longitudinal study has also reported higher HR-QOL scores 
for PD patients versus HD patients after more than 4 years of treatment (Ginieri-
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Coccossis, 2008). Some, but not all studies have reported patients on APD to have 
higher HR-QOL scores compared to CAPD patients; APD patients also had lower 
peritonitis rates and more time for work, family or social activities; nevertheless, 
other authors found no significant differences between both therapies 
(Balasubramanian, 2010; Bro, 1999; Guney, 2010; Rabindranath, 2007). These 
factors should be examined in future HR-QOL and cost-analysis studies of 
patients with ESRD on various modes of dialysis to determine whether the cost 
effectiveness and improved HR-QOL for APD are consistent. 
Many of the HR-QOL findings are consistent with prior literature 
regarding the impact of ESRD on the physical, social and emotional dimensions 
of HR-QOL (Esquivel Molina, 2009; Lii, 2007, Morsch, 2006; Shrestha, 2008). 
What is not captured in norm-based HR-QOL studies, however, are patients‟ 
qualitative perceptions of their life quality and well-being. Notably, during data 
collection, several participants displayed what Albrecht and Devlieger (1999) 
refer to as a „disability paradox;‟ in which some patients have a perception of 
personal health that is discordant with their objective health status and disability. 
For example, a diabetic patient on HD treatment was interviewed sitting in a 
wheelchair due to his left leg being amputated. He lived in a poor neighborhood 
with his wife, daughter, and grandchildren on limited retirement pension and was 
having financial problems, yet he perceived his general health as „excellent.‟ 
Alternatively, a young patient on APD treatment was denying her disease, 
appeared physically healthy and was independent, yet reported to be “living like 
in hell.” Given the limited renal replacement options offered by the Mexican 
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health system, further qualitative or mixed-method (quantitative and qualitative) 
studies regarding the experiences of living with ESRD on CAPD, APD or HD are 
warranted in the growing Mexican ESRD patient population. 
In Mexico, social health institutions have had a policy of PD as the first 
line of treatment and HD as a second option when PD was not successful, which 
could lead to surmising that patients on PD are healthier, more likely to be 
working, more able to travel, have fewer dietary restrictions, reduced financial 
burden and less dependence on the health system. Realistically, however, it means 
that patients on PD require more self-care, adherence to treatment, life-style 
changes, a better understanding of their own medical management, strong health-
team guidance, on-going patient and care-giver training and family support. 
Giving the fact that the CAPD group showed higher values in BMI, systolic blood 
pressure, BUN and glucose levels, number of medications taken and lower 
albumin level, the health team should establish clinical guidelines for a successful 
outcome-oriented PD unit that would include regular patient support, an 
interdisciplinary health team focused on improved quality of care, programmed 
home visits by the health team, and tracking of medical and nursing records. The 
characteristics of dialysis centers showed clinically relevant differences in a study 
by Mazairac and colleagues (2011); therefore, further assessment is needed to 
determine associations between quality of care delivery and HR-QOL outcomes, 
particularly for patients on CAPD. It is notable that APD patients in this study are 
younger than CAPD patients and half of the patients on APD continue to work. 
These factors may contribute to patients on APD experiencing greater „self 
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efficacy.‟ The discrepancies between CAPD and APD patients may be due 
attitudes toward the treatment modality, age, quality of care, availability of 
medical and pharmaceutical resources, lifestyle, health beliefs, and other factors. 
Future investigations are required to determine relationship between these factors 
and HR-QOL outcomes.  
Higher scores (better HR-QOL) among ESRD patients on HD, particularly 
the social domains could reflect the greater attention they receive attending the 
HD clinic several times a week for 3 to 4 hours each visit. These clinic visits also 
allow for continuous care, biochemical and clinical control and, importantly, 
social support they receive from other HD patients and the HD team. In this study, 
for example, all the participants in the HD group received erythropoietin which 
has been considered to improve the HR-QOL (Unruh, 2005; Weisbord, 2008). 
Other authors have reported associations between social support on perceived 
HR-QOL (Gallegos-Carrillo et al., 2009; Spinale et al., 2008; Wu, 2004). Future 
studies that examine HR-QOL, social support and other biomedical factors 
provided ESRD patients on HD in Mexico are warranted.  
Sleep Disorders and ESRD. Perl and colleagues (2006) have suggested 
that sleep disorders could act as markers of inadequate dialysis in ESRD patients 
and the severity of the sleep disorder has been reported to be higher for HD 
compared to PD patients (Eghbali, et al., 2008). Findings from this study indicate 
that the HD group showed higher rates of insomnia symptoms, excessive 
tiredness, un-refreshing (non-restorative) and insufficient sleep. It is common for 
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patients with ESRD to sleep during their daytime HD session, thus contributing to 
difficult or disturbed nighttime sleep, a finding also observed among patients in 
this study.  
While Tang and colleagues (2009) found that sleep apnea was less 
prevalent among APD compared to CAPD patients, the present study noted higher 
rates of witnessed apnea among APD (14.3%) compared to CAPD (10.3%) 
patients. Reasons for these discrepancies are unknown and further studies are 
required, particularly objective studies that use overnight polysomnography. 
Higher rates for RLS (23%) in tandem with daytime sleepiness (26%) among 
patients on CAPD are consistent with other studies (Al-Jahdali, et al., 2009; 
Almeida-Araujo, et al., 2010; Mucsi, 2005). Restless legs syndrome was also 
found to be associated with elevated rates of depression among a sample of US 
military veterans (Baldwin, Bell & Quan, 2005). Disrupted sleep from leg 
movements and/or depression could be major contributors to daytime somnolence 
in these patients.   
Spirituality. Quality of life (QOL) and well-being studies frequently 
include spirituality as a QOL construct. Mexican patients with ESRD in this study 
are predominantly Catholic. Of note, the CAPD group, who showed the poorest 
HR-QOL, was frequently more likely to utilize spiritual/religious practices. These 
findings are consistent with other studies (Davison et al., 2010; Tze-Wah et al., 
2009) and could reflect a logic in which they turn to the divine for hope and 
comfort when they are not experiencing physical improvement. The patients on 
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CAPD also showed higher scores on the LSPS (p=0.06) compared to the APD 
and HD groups. Consistent with prior studies, the use of spiritual/religious beliefs 
and practices reportedly helped the patients with ESRD to endure their disease as 
well as provide methods of coping (Finkelstein, et al., 2007; Kimmel, et al., 2003; 
Patel, et al., 2002).   
Depression and Anxiety. Depression has been demonstrated to be an 
independent factor associated with poor HR-QOL (Cruz et al., 2010). Rates for 
depression in prior studies of patients with ESRD have ranged from 25% to 65% 
(Bilgic, et al., 2007; Drayer et al, 2006; Weisbord, et al., 2005); the overall rate 
for depression in the present study was 11%. Reasons for these differences are not 
known. One might speculate that the high rates of familism (connection with 
family; thereby, high family support) in the Mexican culture might account for the 
lower rates in this population. Further studies are needed to determine if culture 
plays a role in mood in the presence of debilitating illness. To date, this appears to 
be the first study to examine anxiety among Mexican patients with ESRD on three 
types of dialysis. Notably, the patients on CAPD in this study reported the poorest 
HR-QOL and showed higher depression and anxiety scores, albeit not 
significantly so, compared to the other two dialysis groups. This finding does not 
match Kalender and colleagues (2007), who found the higher proportion of 
depressive patients in the HD compared to the CAPD group. The patients on 
CAPD were also more likely to report RLS, which has been correlated with 
higher depression and anxiety rates in a population based study (Sevim et al., 
2004). It is suggested that future studies of sleep disorders by dialysis type include 
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standardized depression and anxiety measures, family histories of these mood 
disorders along with assessment for RLS (patient and family) to determine 
associations between these variables. 
Utility & Cost Analysis. This is the first study to examine the cost-
effectiveness of three dialysis modalities (CAPD, APD and HD). Findings from 
this study support APD as it is less costly and most efficient. One other study 
done in Mexico estimated costs, but did not include HR-QOL for dialysis; the per-
patient cost of HD was 35% higher than PD (Prieto, et al., 2007). Liem and 
colleagues (2008) examined health utility (akin to SF-6D scores) for HD, PD and 
renal therapy (RT) and found no significant differences in utility; however, 
QALY and cost analysis was not included in the study. A cost analysis study that 
compared health utility and lifelong QALY of HD, PD and RT was consistent 
with findings from this study; findings indicated that after RT, PD was the second 
most cost-effective therapy (Kontodimopooulos & Niakas, 2007).   
Some differences in findings relevant to cost findings in this study could 
be related to what was included and available for analysis. Cost for this study was 
based on public purchase information estimated by year and by patient. The cost 
for CAPD and APD did not include taxes, catheter insertion costs, physician or 
nursing fees, monthly visits to the nephrology clinic or patient/primary caregiver 
training, transportation, home visits, or medication. The cost for HD did not 
include taxes, cost for vascular access, tri-weekly transportation to and from the 
clinic, clinic costs, nephrology visits, nursing care, patient/primary caregiver 
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education or medications. Each modality cost was calculated based on average 
number of treatments relevant to the modality type. Future studies of cost 
effectiveness analysis should include these and other related direct and indirect 
costs for each modality type for more exact accounts. Given the high costs for 
clinic visits and trained personnel, however, HD will remain the most costly 
financially.  
Clinical Implications. There are a number of important clinical 
implications to be derived from this study. First, SF-36 and PCS and MCS norms 
are available for Mexican patients with ESRD which can be used as benchmarks 
for HR-QOL outcomes studies, including between modality types. Sleep 
disorders, in particular, and income accounted for 34% of the variance in the 
mental health model. Training in the assessment of and interventions for sleep 
disorders, particularly for advanced practice nurses can be implemented to 
promote healthful sleep that can contribute to improvements in mental HR-QOL. 
A majority of the sleep symptoms can be addressed through nurse/patient 
teaching, cognitive-behavioral approaches, sleep hygiene and other non-
pharmacologic interventions. Nephrologists and physicians who practice sleep 
medicine in Mexico should be apprised of the propensity for witnessed apnea and 
snoring rates of patients with ESRD, particularly patients on APD to determine if 
there are treatment-related contributions to these rates and treat accordingly (e.g., 
weight loss, continuous positive airway pressure breathing). Prior associations 
noted between RLS and mood suggest that treatment of mood disorders of 
dialysis patients might lessen RLS symptoms. Other clinical implications include 
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assessing the best treatment option for the given ESRD patient, whether APD, HD 
or CAPD. Based on findings from this study, APD would be the recommended 
intervention that provides effective cost with best HR-QOL outcomes. The cost 
analysis from this study also lends basis to informing health policy for patients 
with ESRD and their treatment. 
Limitations of the Study. As with any study, there are limitations as well. 
These include, small sample size, costs solely from bids that do not include all 
durables relevant to providing care for HD, APD and CAPD patients, potential for 
participants to want to please the interviewer, which might have influenced 
responses, and data collected from one state in central Mexico, which hinders 
generalizability of findings. The cross-sectional study design cannot infer cause 
and effect relationships between variables. The pilot nature of this study and the 
generous p-value of 0.10 is also a limitation. Future studies will need to recruit 
larger samples of participants within each of the modality types to determine 
consistency of findings with a more stringent level of significance that accounts 
for multiple variables (i.e., Bonferroni correction). 
Summary. Despite any limitations, this study has provided a first-ever 
glimpse of SF-36 norms for Mexican patients with ESRD. Norms for this disorder 
have yet to be established for patients with ESRD from other countries. As well, 
findings have identified sleep disorders experienced by patients within dialysis 
modalities, and these sleep disorders impinge greatly on the mental health of 
ESRD patients. Identification of the sleep disorder types alone can inform medical 
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and nursing curriculum in Mexico for assessing and treating sleep disorders that 
can lead to improved HR-QOL. Importantly, the SF-6D scores derived from the 
SF-36 in tandem with QALY data have provided insight into the most efficacious 
form of dialysis delivery that is cost effective and supports improved HR-QOL, 
the APD modality.  
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Table 1. 
Instruments Used in the Study 
Construct Enroll-
ment 
Inter- 
view 
Medical 
records 
Instrument 
name 
Variable for analysis 
Modality of 
Dialysis. 
Independent 
Variable 
X  
 
Observer data 
form 
Groups: Continuous 
Ambulatory Peritoneal 
Dialysis [CAPD], Automated 
Peritoneal Dialysis [APD], 
and Hemodialysis [HD])  
Social 
Roles 
 X 
 
Demographics 
data form 
Age, gender, marital status, 
work status, SES, education 
level, religion, social and 
family support. 
Clinical 
background 
  X 
Clinical and 
biomarkers 
data form 
Primary cause of ESRD 
(Diabetes, glomerulonephritis, 
hypertension/ischemic, 
polycystic kidney disease, 
transplant failure, other, 
unknown). Number of 
hospitalizations, time since 
treatment,  peritonitis, type of 
catheter, dialysis dose, 
number of anti-hypertensive 
drugs, use of erythropoietin, 
number of HD sessions per 
week, last home visit by the 
dialysis team; Urea, 
creatinine, hematocrit, BUN. 
Anxiety & 
Depression 
 X  HADS 
Scores for 7 anxiety & 7 
depression items.  
Sleep 
Disorders 
 X 
 
Sleep Habits 
& Epworth 
Subjective scores for snoring, 
apnea, insomnia/other sleep 
symptoms, RLS, EDS. 
 
CAM 
practices 
 X 
 
CAM 
practices form 
Scores on use, relation with 
dialysis, and evaluation of 
helpfulness. 
Spirituality  X  LSPS Subscale score. 
PCS  X 
 
SF-36 Scales/Physical Health. 
MCS 
 X  SF-36 Scales/Mental Health. 
 
Costs 
    Averages from ISSSTE 
contracts 
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Table 2  
City of Origin and Dialysis Modality of the Study Participants 
Guanajuato State ISSSTE 
City 
CAPD 
(n=39) 
APD 
(n=42) 
HD 
(n=40) 
Total 
(N=121) 
Celaya 12 12 10 32 
Irapuato 10 5 10 25 
Guanajuato 7 15 10 34 
León 10 10 10 30 
Note: ISSSTE (Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado);  
APD (Automated Peritoneal Dialysis); CAPD (Continuous Ambulatory Peritoneal Dialysis);  
HD (Hemodialysis). 
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Table 3                                                                                                                                                                                
Socio-demographic Characteristics of Study Participants by Dialysis Modality 
Characteristics 
 Treatment Modality 
CAPD (n=39) APD (n=42) HD (n=40) p value TOTAL 
(N=121) 
n % n % n %  N % 
Gender         
 
 
       Female 22 56.4 14 33.3 18 45.0 0.11 54 44.6 
      Male 17 43.6 28 66.7 22 55.0  67 55.4 
Marital Status          
     Widowed 8 20.5 5 11.9 8 20.0 0.77 21 17.4 
     Single 4 10.3 4   9.5 5 12.5  13 10.7 
     Divorced 3   7.7 1   2.4 2   5.0  6   5.0 
     Married 24 61.5 32 76.2 25 62.5  81 66.9 
Smoking          
     Never 17 43.6 19 45.2 23 57.5 0.17 59 48.7 
     Current 1   2.6 4   9.5 0   0  5   4.1 
     Past 21 53.9 19 45.2 17 42.5  57 47.1 
Alcohol*          
     Never 18 69.2 12 37.5 16 59.3 0.04 46 54.1 
     Current 0      0 0   0 0   0  0   0 
     Past 8 30.8 20 62.5 11 40.7  39 45.9 
Medical Insurance          
     ISSSTE 35 89.7 42 100 37 92.5 0.11 114 94.2 
     ISSSTE/IMSS 2   5.1 0  3   7.5  5   4.1 
     ISSSTE/SP 2   5.1 0  0   0  2   1.7 
 Income(per year 
USD)* 
         
     None 7 17.6 10 23.8 4 10.0 0.05 21 17.4 
     < $1,608 5 12.8 0    0 8 20.0  13 10.7 
     $1,608-3,215 7 17.9 5 11.9 6 15.0  18 14.9 
     $3,216-4,823 4 10.3 3   7.1 10 25.0  17 14.1 
     $4,824-6,431 4 10.3 9 21.4 4 10.0  17 14.1 
     $6,432-8,040 2   5.1 4   9.5 2   5.0  8   6.6 
     >  $8,040 10 25.6 11 26.2 6 15.0  27 22.3 
Religion          
     Catholic 35 89.7 39 92.9 38 95.0 0.59 112 92.6 
     Christian 1   2.6 2   4.8 2   5.0  5   4.1 
     Jehovah‘s 
Witnesses 
2   5.1 1   2.4 0   0  3   2.5 
     Other 1   2.6 0   0 0   0  1   0.8 
Working*          
     Yes 2   5.3 14 33.3 3   7.5 0.002 19 15.8 
     No 35 92.1 26 61.9 33 82.5  94 78.3 
     Occasional 1   2.6 2   4.7 4 10.0  7   5.8 
 M SD M SD M SD p value M SD 
Education (years)* 
8.2 7.4 11.4 6.4 8.7  5.9 0.06 9.5 6.7 
People in housing 
4 1.8 4.0 1.5 3.67 1.3 0.53 3.9 1.5 
Age* 64.2   8.9 53.1 13.4 60.8 14.
7 
0.00 59.3 13.
4 
Note:*p < 0.1. APD (Automated Peritoneal Dialysis); CAPD (Continuous Ambulatory  
Peritoneal Dialysis); HD (Hemodialysis).  
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Table 4 
 Clinical Characteristics of Study Participants by Dialysis Modality-continuous 
Variables 
Characteristics 
 Treatment Modality 
CAPD             APD HD 
p 
value 
TOTAL 
n M(SD) n M(SD) n M(SD)  N M(SD) 
          
BMI 32 27.7(5.6) 38 26.0(4.0) 34 24.8(5.4) 0.06 104 26.1(5.1) 
Systolic BP 25 147.7(31.7) 27 140.1(17.4) 29 144.7(31.2) 0.60 81 144.1(27.44) 
Diastolic BP 25 78.9(16.6) 27 84.9(14.1) 29 75.4(18.9) 0.11 81 79.7(17.0) 
Comorbidities
 
29 3.1(0.9) 32 3.2(1.2) 30 2.7(1.2) 0.19 91 3.0(1.1) 
Hb 26 10.8(2.1) 27 11.5(2.9) 28 11.3(3.9) 0.72 81 11.2(3.0) 
Albumin 22 3.2(0.7) 26 3.5(0.6) 15 3.9(0.5) 0.002 63 3.5(0.7) 
Creatinine 27 8.3(3.2) 31 11.8(4.3) 29 6.7(3.7) 0.000 87 9.0(4.3) 
Urea 28 91.7(35.3) 31 102.0(39.3) 29 94.9(42.0) 0.58 88 96.4(38.8) 
BUN 5 61.0(9.5) 7 53.5(15.2) 28 45.3(19.3) 1.95 40 48.7(18.3) 
Glucose 25 129.1(56.4) 30 115.7(55.1) 27 125.4(49.2) 0.47 82 123.0(53.3) 
 # Medications 29 6.8(2.6) 31 6.6(3.1) 29 5.9(2.0) 0.96 89 6.4(2.5) 
Time in HD
b 
- - - - 37 26.4(19.8) -- 37 25.1(19.3) 
Time in PD
b 
36 15.3(12.7) 41 37.4(22.1)   -- 79 26.4(21.5) 
Note:
b
Months on the dialysis treatment  modality.  
*p < 0.1 
BMI (Body Mass Index); BP (Blood Pressure); Hb (Hemoglobin); BUN (Blood Urine Nitrogen); 
APD (Automated Peritoneal Dialysis); CAPD (Continuous Ambulatory Peritoneal Dialysis); HD 
(Hemodialysis). 
 
 
77 
Table 5 
Clinical History of Study Participants by Dialysis Modality-categorical Variables  
      
     CAPD       APD HD    TOTAL 
n % n % n % p 
value 
N % 
            
Etiology*         
 
 
      Diabetes 31 79.5 32 76.2 24 60.0 0.16 87 72.0 
     Hypertension 6 15.4 5 11.9 6 15.0  17 14.0 
     Other    2 5.1 5 11.9 10 25.0  17 14.0 
 # 
Hospitalizations 
in past year 
         
     0 17 43.6 21 50.0 19 47.5 0.49 57 47.1 
     1 12 30.8 12 28.6 8 20.0  32 26.4 
     2 3 7.7 6 14.3 9 22.5  18 14.9 
     3 3 7.7 1 2.4 2 5.0  6 5.0 
     4 2 5.1 0 0 0 0  2 1.7 
     >5 2 5.1 2 4.8 2 5.0  6 5.0 
Days 
Hospitalized (in 
(in p 
         
 in past year          
Never 17 43.6 21 50.0 19 47.5 0.82 57 47.1 
     < 3  10 25.6 10 23.8 10 25.0  30 24.8 
     4-10 7 17.9 8 19.0 8 20.0  23 19.0 
     11-15 3 7.7 1 2.4 0 0  4 3.3 
     15-30      2 5.1 2 4.8 2 5.0  6 5.0 
     >30 0 0 0 0 1 2.5  1 0.8 
# 
Antihypertensive 
 
 
 
         
     0 10 25.6 7 16.7 14 35.9 0.37 31 25.8 
     1 16 41.0 18 42.9 15 38.5  49 40.8 
     2-3 10 25.6 11 26.2 9 23.1  30 25.0 
     4 + 3 7.7 6 14.3 1 2.6  10 8.3 
Erythropoietin 
Use 
         
     Yes 34 87.2 35 83.3 40 100 0.06 109 90.1 
     No 5 12.8 7 16.7 0 0  11 9.0 
          
Note:*p < 0.1 
APD (Automated Peritoneal Dialysis); CAPD (Continuous Ambulatory Peritoneal Dialysis);  
HD (Hemodialysis). 
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Table 6 
 Prevalence of Self-reported Sleep Disorders by Dialysis Type 
Sleep Disorders Total 
(N=121) 
CAPD 
(n=39) 
APD 
(n=42) 
HD 
(n=40) 
p-value 
 
n (%) n (%) n (%) n (%) 
 
Obstructive sleep apnea 3 (2.7) 1 (2.8) 2 (5.1) 0 0.41 
Witnessed apnea* 12 (10.0) 4 (10.3) 6 (14.3) 2 (5.1) .038 
Snoring* 23 (21.1) 7 (19.4) 10 (25.6) 6 (17.6) .067 
Insomnia 45 (37.2) 13 (33.3) 13 (30.9) 19 (47.5) 0.25 
Excessive Tiredness 25 (20.7) 8 (20.5) 8 (19.0) 9 (22.5) 0.93 
Unrefreshing sleep* 42 (34.7) 16 (41.0) 9 (21.4) 17 (42.5) 0.08 
Insufficient sleep 34 (28.1) 10 (25.6) 12 (28.6) 12 (30.0) 0.90 
Restless legs syndrome 23 (19.0) 9 (23.1) 7 (16.7) 7 (17.5) 0.73 
EDS (Epworth >10) 
 
25 (19.0) 10 (25.6) 5 (11.9) 10 (25.0) 0.22 
 M (SD) M (SD) M (SD) M (SD) M (SD) 
No. sleep symptoms past 
year 
1.0 (1.5) 0.9 (1.2) 1.2 (1.8) 0.9 (1.5) 0.53 
Note:*p < 0.1 
SHQ (Sleep Habits Questionnaire); APD (Automated Peritoneal Dialysis); CAPD (Continuous 
Ambulatory Peritoneal Dialysis); HD (Hemodialysis). 
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Table 7 
Means and Standard Deviations for HADS by Dialysis Modality and Prevalence 
of Normal, Borderline and Abnormal Anxiety and Depression Rates by Dialysis 
Modality 
HADS 
CAPD APD HD p-
value 
TOTAL 
M (SD) M (SD) M (SD)  M (SD) 
Total Anxiety 
Score* 
7.3 (6.0) 5.1 (5.2) 3.8 (3.9) 0.03 5.4 (5.3) 
Total Depression 
Score* 
6.5  (5.6) 6.2 (5.2) 3.8 (2.9) 0.05 5.5 (4.8) 
 n(%) n(%) n(%)  n(%) 
Anxiety*    0.060  
   Normal (0-7) 18 (62.1) 23 (71.9) 26 (86.7)  67 (73.6) 
   Borderline (8-10) 4 (13.8) 2 (6.3)  1 (3.3)  7 (4.5) 
   Abnormal (11-21) 7 (24.1) 7 (21.9) 3 (10.0)  17 (18.7) 
Depression*    0.045  
   Normal (0-7) 21 (72.4) 21 (65.6) 27 (90.0)  69 (75.8) 
   Borderline (8-10) 3 (10.3) 6 (18.8) 3 (10.0)  12 (13.2) 
   Abnormal (11-21) 5 (17.2) 5 (15.6) 0  10 (11.0) 
Note:*p < 0.1 
HADS (Hospital Anxiety and Depression Scale); APD (Automated Peritoneal Dialysis); CAPD 
(Continuous Ambulatory Peritoneal Dialysis); HD (Hemodialysis). 
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Table 8 
Self-reported Spirituality and Spiritual Practices by Treatment Modality 
Spirituality TOTAL 
(N=79) 
CAPD 
(n=26) 
APD  
(n=30) 
HD 
(n=23) 
p-
value 
 n (%) n (%) n (%) n (%)  
 
Consider yourself a 
spiritual person* 
 
37 (46.8) 
 
14 (53.8) 
 
9 (30.0) 
 
14 (60.9) 
 
.06 
Frequent 
spiritual/religious 
practices 
38 (48.1) 16 (61.5) 10 (33.3) 12 (52.2) .10 
Help to endure your 
disease 
57 (72.1) 19 (73.1) 19 (63.3) 19 (82.6) .29 
 M (SD) M (SD) M (SD) M (SD)  
Latino Spiritual 
Perspective Scale* 
5.5 (0.7) 5.7 (0.5) 5.3 (0.7) 5.6 (0.8) .06 
Note:*p < 0.1 
APD (Automated Peritoneal Dialysis); CAPD (Continuous Ambulatory Peritoneal Dialysis);  
HD Hemodialysis). 
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Table 9 
Mean Scores and Standard Deviations for SF-36 Domains, Physical and Mental 
Composite Scores and SF-6D Scores by Dialysis Modality 
     
SF-36 domain 
CAPD 
Mean (SD) 
APD 
Mean (SD) 
HD 
Mean (SD) 
p value Total Mean 
Physical Function* 30.38 (29.3) 43.69 (28.9) 43.50(29.20) 0.072 39.34(29.1) 
Role Physical* 17.95 (42.6) 35.12 (42.2) 37.50 (42.7) 0.089 30.37(42.5) 
Bodily Pain 61.79 (36.4) 71.90 (36.0) 60.44 (36.5) 0.300 64.85(36.3) 
General Health 42.31 (24.5) 44.52 (24.1) 53.12 (24.5) 0.118 46.65(24.4) 
Vitality* 43.72 (29.0) 53.81 (28.7) 61.25 (29.0) 0.029 53.02(28.9) 
Social 
Functioning* 
58.01 (32.6) 70.53 (32.3) 81.56 (32.7) 0.007 70.14(32.5) 
Role Emotional 59.83 (42.9) 70.63 (42.4) 76.25 (43.0) 0.229 69.01(42.8) 
Mental Health 65.23 (24.5) 72.00 (24.2) 72.80 (24.5) 0.323 70.08(24.4) 
PCS 30.13 (11.4) 34.65 (9.8) 34.02 (12.5) 0.156 32.98(11.3) 
MCS* 48.10 (15.6) 51.59 (13.4) 55.05 (9.8) 0.067 51.61(13.3) 
SF-6D Score* 0.59 (0.1) 0.69 (0.1) 0.68 (0.2) 0.009 0.65 (0.2) 
Note:*p < 0.1 
PCS (Physical Composite Score); MCS (Mental Composite Score); SD (Standard Deviation); 
APD (Automated Peritoneal Dialysis); CAPD (Continuous Ambulatory Peritoneal Dialysis); HD 
(Hemodialysis). 
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Table 10 
Comparison of SF-36, PCS and MCS Scores for Mexicans with ESRD, Mexican 
General Population Norms, US General Population Norms and US Norms for 
Persons with Hypertension, Type 2 Diabetes and Congestive Heart Failure  
      
SF-36 
domains 
 
Mexican 
ESRD 
Patients  
(N=121) 
 
 
M(SD) 
Mexican 
General 
Population 
Norms* 
(N=5,961) 
 
M(SD) 
 
 
US General 
Population 
Norms** 
(N=2,474) 
 
 
M(SD) 
 
US Norms 
Hypertension** 
(N=2,089) 
 
 
 
M(SD) 
 
US Norms 
Type 2 
Diabetes** 
(N=541) 
 
 
M(SD) 
US Norms 
CHF** 
(N=216) 
 
 
 
M(SD) 
Physical 
Function 
39.3(29.1) 89.6(23.2) 84.1(23.3) 73.4(26.4) 87.7(28.7) 47.5(31.0) 
Role Physical 30.4(42.5) 88.7(30.9) 80.9(34.0) 62.0(39.4) 56.8(41.7) 34.4(39.7) 
Bodily Pain 64.9(36.3) 85.5(23.2) 75.1(23.7) 72.3(24.4) 68.5(26.5) 61.7(31.0) 
General 
Health 
46.7(24.4) 52.2(15.4) 72.0(20.3) 63.3(19.7) 56.1(21.1) 47.1(24.2) 
Vitality 53.0(28.9) 70.7(15.4) 60.9(21.0) 58.3(21.4) 55.7(21.6) 44.3(24.4) 
Social 
Functioning 
70.1(32.5) 75.1(15.4) 83.8(22.7) 86.7(20.7) 82.0(25.0) 71.3(33.1) 
Role 
Emotional 
69.0(42.8) 88.9(23.2) 81.3(33.0) 76.7(35.7) 75.6(36.6) 63.7(43.0) 
Mental 
Health 
70.1(24.4) 72.1(15.4) 74.7(18.1) 77.9(17.4) 76.7(18.3) 74.7(21.3) 
PCS 33.0(11.3) 79.0(15.4) 50.0(10.0) 44.6(11.3) 39.3(11.3) 31.0(10.6) 
MCS 51.6(13.3) 76.7(15.4) 50.0(10.0) 49.2(10.6) 47.9(11.4) 45.7(12.5) 
Note:*Duran-Arenas & Cols (2004); **Ware et al. (1994, 1997)  
PCS (Physical Composite Score); MCS (Mental Composite Score); M (Mean); SD (Standard 
Deviation); CHF (Congestive Heart Failure); ESRD (End-Stage Renal Disease); US (United 
States) 
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Table 11  
HR-QOL (PCS and MCS) Subgroup Differences by Dialysis Modality* 
   Dialysis Modality† 
 F-
value 
p-
value** 
(1) CAPD 
n=39 
(2) APD 
n=42 
(3) HD 
n=40 
   LSMean 
(SE) 
LSMean 
(SE) 
LSMean 
(SE) 
HR-QOL** 3.36 .002 .56 (.03)
a,b
 .68 (.03)
a
 .64 (.03)
b
 
    Dialysis type** 3.76 .03    
    Sleep   
    disorders** 
12.76 .0007    
    Comorbidities 2.87 .10    
    Spirituality 1.40 .24    
    CAM use 1.85 .18    
    Sex 0 .95    
    Age 0.05 .82    
    Income** 4.61 .04    
Note:* Controlling for age, sex, income, co-morbidities, sleep disorders, spirituality, CAM 
(Complementary and Alternative Medicine) use. 
**Statistically significant findings. 
†Contrast of 3 level categorical variables at p<.05: a=1 vs. 2; b=1 vs. 3; c=2 vs. 3.  
HR-QOL (Health-Related Quality of Life); PCS (Physical Composite Scale); MCS (Mental 
Composite Scale). APD (Automated Peritoneal Dialysis); CAPD (Continuous Ambulatory 
Peritoneal Dialysis); HD (Hemodialysis). 
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Table 12 
Physical Composite Summary (PCS) Subgroup Differences by Dialysis Modality* 
 
   Dialysis Modality† 
 F-
value 
p-
value** 
(1) CAPD 
n=39 
(2) APD 
n=42 
(3) HD 
n=40 
   LSMean 
(SE) 
LSMean 
(SE) 
LSMean 
(SE) 
SF-36 Physical 
Component Scale 
(PCS) 
1.21 .30 31.39 
(2.45) 
33.73 
(2.28) 
34.82 
(2.53) 
        Dialysis type 0.48 .62    
        Sleep  
        disorders 
1.59 .21    
        Comorbidities 2.57 .11    
        Spirituality 1.38 .24    
        CAM use 0.41 .53    
        Sex 1.94 .17    
        Age 0 .96    
        Income 0.91 .34    
Note:* Controlling for age, sex, income, co-morbidities, sleep disorders, spirituality, CAM 
(Complementary and Alternative Medicine) use. 
**Statistically significant findings. 
†Contrast of 3 level categorical variables at p<.05: a=1 vs. 2; b=1 vs. 3; c=2 vs. 3.  
APD (Automated Peritoneal Dialysis); CAPD (Continuous Ambulatory Peritoneal Dialysis); HD 
(Hemodialysis). 
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Table 13  
Mental Composite Summary (MCS) Subgroup Differences by Dialysis Modality* 
   Dialysis Modality† 
 F-
value 
p-
value** 
(1) CAPD 
N=39 
(2) APD 
N=42 
(3) HD 
N=40 
   LSMean 
(SE) 
LSMean 
(SE) 
LSMean 
(SE) 
SF-36 Mental 
Component Scale 
(MCS)** 
4.02 .0004 42.99 
(2.49)
 a,b
 
52.02 
(2.32)
 a
 
51.35 
(2.56)
 b
 
    Dialysis type** 3.98 .02    
    Sleep 
disorders** 
19.6
0 
<.0001    
    Comorbidities 2.51 .12    
    Spirituality 0.02 .90    
    CAM use 0.86 .36    
    Sex 1.76 .19    
    Age 0 .95    
    Income** 4.48 .04    
Note:* Controlling for age, sex, income, co-morbidities, sleep disorders, spirituality, CAM 
(Complementary and Alternative Medicine) use. 
**Statistically significant findings. 
†Contrast of 3 level categorical variables at p<.05: a=1 vs. 2; b=1 vs. 3; c=2 vs. 3.  
APD (Automated Peritoneal Dialysis); CAPD (Continuous Ambulatory Peritoneal Dialysis); HD 
(Hemodialysis). 
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Table 14 
Cost Analysis of the Different Dialysis Modalities of the Study 
 Cost Effectiveness 
(QALY) 
Incremental 
Cost 
Incremental 
Effectiveness 
(QALY) 
ICER (IC/IE) 
CAPD $286 0.71    
APD $606 2.05    
HD $825 1.44    
APD 
vs. 
CAPD 
  $320 1.34 $238.80/QALY 
HD vs. 
CAPD 
  $539 0.71 $759.15/QALY 
HD vs. 
APD 
  $219 -0.61 
APD 
DOMINATED 
Note:APD (Automated Peritoneal Dialysis); CAPD (Continuous Ambulatory Peritoneal Dialysis); 
HD (Hemodialysis). QALY (quality-adjusted life year), ICER (Incremental Cost-Effectiveness 
Ratio); IE (Incremental effectiveness); IC (Incremental Cost). 
  
87 
 
 
Figure 1. Mexican Health System (Frenk, Sepúlveda, Gómez-Dantés, & Knaul, 
2003). 
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Figure 2. Mexican Health System structural change (Frenk et al, 2003). 
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Figure 3. Study participants flow. 
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Figure 4.Mean values for SF-36 domains by treatment modality.* 
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APPENDIX A  
INFORMED CONSENT  
  
92 
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APPENDIX B  
1. ENGLISH INSTRUMENT  
  
95 
 Demographic Information 
 
Instruction: Answer the following questions filling the empty spaces or the circles  
at the answers. Your information will be completely confidential. 
  
1 Which is the date of today?  Month____ Day ____ Year _____ 
 
2. Which is your stature? _____ cm  
 
3. Which is your weight? _____ kg 
 
4. ¿Which is your sex?  
  1 Male 
  0 Female 
 
5. How old are you?       ________ (Number of years) 
 
6. Your birthday is Month ____ Day ____ Year _____ 
 
7. Blood Pressure _________________________Taken (date)__________________ 
 
7. Where was you born (city, state, & country)? ________________________________  
 
8. Where have you lived most of your adult life (city, state, & country)? ______________ 
 
9. How many years of school have you completed? _______ (Number of years) 
 
10. What level of school have you completed?  
  0 Never attended to school 
  1 Less tan 6 years (primary school) 
  2 6 to 8 years (secondary school) 
  3 9 to 11 years (preparatory schoool) 
  4 Preparatory 
  5 Associated graduated or equivalent 
  6 Undergraduate or equivalent 
  7 Masters or equivalent 
  8 Doctorate or equivalent 
 
11. Marital Status:  
  4 Married/living with partner 
  3 Separated/Divorced 
  2 Single 
  1 Widow 
 
12.  Counting yourself, how many people live in your house or department? Please 
include adults, babies, children that live with you.   
Number of people: _____________ 
 
13. Have you ever smoked? 
  0 Never smoked  
 1 I somoke 
  2 Before I smoked but no longer  
96 
14.  What type of medical insurance do you have?  (Choose all that applies) 
  
None…. ……………………………………..…..…..   1 _____ 
IMSS…………………………………………….…..….   2 _____ 
ISSSTE………………………………………………....   3 _____ 
Private insurance (ej. Prudencial)………………………..…..  4 _____ 
PEMEX………………………………………………….   5 _____ 
SEDENA…………………….………………………….   6 _____ 
Popular Insurance………………………………………..   7 _____ 
 
  
15.  Which was your total income last month (considera ll the entrances as Money from 
the government for children, unemployment, disability or social security).  Remember that 
all the answers are confidential. 
 
Please mark with an X your answer for the following information ($54.47): 
 
None……………… ……………………………………………… 1 _____ 
 
Less tan 1 Minimum Salary (SM)($1661.335)…………………… 2 _____ 
Between 1SM and less than 2SM 
($1661.335- 3322.67)………...…………………………………… 3 _____ 
Between 2SM and less than 3SM 
($3322.67-4984.005).………………….……..…………………… 4 _____ 
Between 3SM and less than 4SM 
($4984.005-6645.34).………………….……..…………………… 5 _____ 
Between 4SM and less than 5SM 
($6645.34-8306.675).………………….……..…………………… 6 _____ 
5SM or more 
($8306.675-more)…………………………..….………….……….. 7 _____ 
 
16. Which religión do you practice? 
 Catholic  1_______ 
 Cristian   2_______ 
 Jehova Witnesses 3_______ 
 Jewish   4_______ 
 Buddhist     5_______ 
 Other_____________ 6_______ 
 
17. How many people are in your family?  
In what position are you? 
 
18. ¿What do you do for a living? 
Do you continue working              Yes_____1 
         No____2 
               Not as before ____3  
 
19. How many times in a month do you come to this clinic due to your 
treatment?__________ 
 
20. How much Money do you spend in average whenever you come to this 
clinic?__________ 
 
21. Do you lose your day of work, or your companion, whenever you/she comes? 
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Medical Background 
 
1. Which is the disease that caused your renal insufficiency? 
Diabetes Mellitus   1___ 
Hypertension    2___ 
Poliquistic kidneys   3___ 
Glomerulonefritis   4___ 
Other _____________  5___ 
Don’t know    6___ 
 
2. Which has been your dialysis treatment for the last six monts?  
 
Continuous ambulatory peritoneal dialysis   (CAPD) 1____ 
Automated peritoneal dialysis (APD)   2____ 
Hemodialysis (HD)     3____ 
 
3. If you have peritoneal dialysis, 
 
How many changes you do by day?   One or two     _____1 
        3 to 4             _____2 
        5 to 6             _____3 
       Not applicable_____4 (APD)  
 
How do you apply the treatment generally? No. Of bags     ____2000ml____1 
              5000ml____2 
 
      Concentration  1.5%___ 
         2.5%___ 
         4.25%___ 
 
What type of catheter do you have? 
                    Tenckhoff          ____1 
        Pig tail    ____2 
        Swan neck ____3 
        Other  ____4 
        Don’t know ____5 
 
When was the catheter installed?               Less than 1 year            ____1 
       1 year to 2 years   ____2 
       De 3 a 5 años  ____3 
       Más de 5 años  ____4 
 
When did you have your transfer line changed? 
Less than 6 months           ___1 
   More tan 6 months              ___2 
 
4. If you have hemodialysis, 
 
1. Which shift are you scheduled?_____________  
Mañana____1 
 Tarde  ____2 
 Noche   ____3 
 Variable____4 
 
2. How much time do you wait before going to treatment?______ 
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3. How much time are you connected to the hemodialysis machine?_______  
 More than 4 hours  ____1 
 Between 3 & 4 hrs. ____2 
 Less than 3 hrs.     ____3 
 
4. How many times per week do you have your treatment?     
One _____1 
 Two _____2 
 Three _____3 
 Four      _____4 
 Five or more_____5 
 
5. How many times where you hospitalized this last year?     
One  _____1 
 Two  _____2 
 Three  _____3 
 Four   _____4 
 Five or more _____5 
 
    6. How long where you hospitalized the last time? 
  Three days or less _____1 
      4 to 10 days  _____2 
  11 to 15 days  _____3 
  15 to 30 days  _____4 
  More than 1 month _____5 
  
    7. Which was the cause for hospitalization?___________________________ 
 
5. If you take antihypertensives, how many do you take? 
1_____ 
2_____ 
3_____ 
4_____ 
 
6. When was the most recent home visit you had from the health team? 
Less than 1 month  _____1 
More than 1 month  _____2 
More than three months  _____3 
More than six months      _____4 
 
7. Who visited you? 
Physician  _______1 
Nurse      _______2 
Social worker      _______3 
Other__________ _______4 
 
8. When did you have your last medical consultation (nephrologyst)? 
Less than one month   _____1 
More than one month  _____2 
More than three months  _____3 
More than six months      _____4 
 
9. Do you have a personal caregiver? Yes_____1  
No____2 
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10. What is your relationship with the caregiver? 
Family(son or daughter)  _____1 
Family (husband/wife)  _____2 
Family (parents)              _____3 
Family (brother/sister)  _____4 
Family(other_____)  _____5 
Not family   _____6 
 
 
11. Who performs the Dialysis treatment? 
Family(son or daughter)  _____1 
Family (husband/wife)  _____2 
Family (parents)              _____3 
Family (brother/sister)  _____4 
Family(other_____)  _____5 
Not family   _____6 
 
12. Did you/they receive training?  Yes_____1 
No____2 
 
13. Where was the training received? ______________________________ 
 
14. How many months ago?  Less than three months _____1 
Three to 6 months _____2 
6 months to 1 year _____3 
More than 1 year _____4 
More than 3 years _____5 
 
15. What kind of insulin do you use? 
NPH  ________1 
Slow action ________2 
Fast action        ________3 
Don’t use ________4 
 
16. How do you use insulin? 
Intraperitoneal _______1 
Subcutaneus ______2 
 
17. Do you use erytropoyetin regularily? 
Yes_____1 
No    ____2 
 
18. When was the last time you use it?_________________ 
 
19. Recent lab data:  19.1 Hemoglobin________. 19.2 Albumin_______.  
                     19.3 Creatinin_______.19.4 Urea_______. 19.5 BUN______. 
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Use of Complementary Alternative Medicine 
                      
1. Have you use a therapy or folk medicine like the following? 
Acupuncture     ______1 
Ayurveda     ______2 
Biofeedback     ______3 
Chelation therapy    ______4 
Chiropractic     ______5   Comments_______ 
Energy healing therapy                             ______6 _____________ 
Hypnosis     ______7 _____________ 
Massages     ______8 
Naturopathy     ______9 
Curandero                         _____10 
Movement therapies                _____11  
Herbs                  _____12  
No-vitamin supplements                _____13 
Vitamins y minerals    _____14 
Homeopathy      _____15 
Special Diets          _____16 
Yoga/tai chi/qi gong     _____17 
RelaxationTechniques     _____18 
Prayers                                   _____19 
Brujeria (barrido)    _____20 
Otros _______________   _____21 
 
2. Which of them have you used within the last 12 months? 
 
3. How many times have you visited the therapy provider? 
 
Just once   ____1 
Les than 5 times ____2 
 5 to 15 times      ____3 
More than 15 times ____4 
 
4. For what condition did you consulted this people? ____________    
related to CKD   ______1 
No.related to CKD_____2 
 
5. Did you receive and take a treatment prescribed by this people?      
Yes________1 
     No________2 
 Specify_______________________________________________________ 
 
6. Do you consider the treatment received to be effective?  
 Yes_____1 
No____2 
 ¿why?________________________________________________________ 
 ________________________________________________________________ 
 
7. Have you ever self-medicated?       
 Yes_____1 
No____2 
 ¿why?________________________________________________________ 
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Most people sleep at night, but some people work at night and sleep in the day. Your 
main sleep period is the time of day or night when you usually sleep the longest. Think 
about your main sleep period when you answer questions on this survey.  
 
Instructions: Fill in the circle in front of the answer that is correct for you on 
Question 1. 
 
1. When is your main sleep period? 
  0 Night  
  1 Day 
  2 Sometimes in the day and sometimes at night 
 
Instructions: Write a number in the blank to answer Questions 2, 3, and 4.  
 
2. How many minutes does it usually take you to fall asleep at your main sleep period?  
 
_____ _____ (Number of minutes) 
 
3. How many hours of sleep do you usually get during your main sleep period on 
weekdays or days you work? 
 
_____ _____ (Number of hours) 
 
4. How many hours of sleep do you usually get during your main sleep period on 
weekends or days you do not work?     
        
____ _____   (Number of hours) 
 
Instructions: Fill in the circle in front of the answer that is correct for you on 
Question 5. 
 
5. Do you try to make time in your schedule for a nap?  
  0 Rarely  
  1 Sometimes 
  2 Often 
  3 Almost everyday 
 
Instructions: Write a number in the blank to answer Question 6. 
 
6. Whenever you do nap, how long do you sleep? _________ (minutes) 
 
 
 
Please continue on the next page 
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7. Whenever you do nap, what are your reasons for taking a nap in the afternoon? 
 
       A.  1 Yes      0 No    I do not get enough sleep at night. 
 
       B.  1 Yes     0 No    I nap due to illness or for medical reasons. 
 
       C.  1 Yes     0 No    I nap because it makes me feel refreshed in general. 
 
       D.  1 Yes                  0 No    Other reason(s). Please explain: _______________ 
 
        __________________________________________________________________ 
 
Instructions: Questions 8, 9, and 10 are about the quality of your sleep during a 
typical main sleep period. Fill in the circle in front of the answer that is correct for 
you. 
 
8. In general, how would you rate the quality of your sleep? 
 
  1 Light (I awaken too easily) 
  2 Somewhat light (I awaken easily) 
  3 Moderate (I sometimes awaken, but not easily) 
  4 Somewhat deep (I sleep well) 
  5 Deep (I sleep very well) 
 
9. In general, how would you rate the quality of your sleep time? 
  
 1 Short (I feel like I just went to sleep even if I slept for 8 hours) 
  2 Somewhat short (I feel like I slept for 2 hours even if I slept for 8 hours) 
  3 Moderate (I feel like I slept for 4 hours even if I slept for 8 hours) 
  4 Somewhat long (I feel like I slept for 6 hours even if I slept for 8 hours) 
  5 Long (I feel like I slept for a full 8 hours or more even if I slept for 8 
hours) 
 
10. In general, how would you rate the quality of your sleep? 
  
 1 Restless (I toss and turn during a lot and my sleep is not restful) 
  2 Somewhat restless (I toss and turn a little and my sleep is not restful) 
  3 Moderate (I toss and turn and my sleep is a little restful) 
  4 Somewhat restful (I do not toss and turn very much and get restful sleep) 
  5 Restful (I do not toss and turn and get restful sleep) 
 
 
 
 
 
 
 
Please continue on the next page 
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Instructions: Questions in the table below are about how often you have sleep 
problems. Circle the number that best describes how often you have the problem. 
 
 
 
11. How often do you…? 
Never Rarely 
(1 day 
a 
month) 
Sometimes 
(2 – 4 days 
a month) 
Often 
(1 – 3 
days 
a 
week) 
Almost 
Always 
(4 or 
more 
days a 
week) 
A 
 
Have trouble falling asleep 0 1 2 3 4 
B 
Wake up during the night and 
have difficulty getting back to 
sleep 0 1 2 3 4 
C 
Wake up too early in the 
morning and are unable to get 
back to sleep 0 1 2 3 4 
D 
Feel unrested during the day, 
no matter how many hours of 
sleep you had 0 1 2 3 4 
E 
Feel excessively (overly) 
sleepy during the day 0 1 2 3 4 
F 
 
Not get enough sleep 0 1 2 3 4 
G 
Take sleeping pills or other 
medication to help you sleep 0 1 2 3 4 
H 
Have nasal stuffiness, 
obstruction, or discharge at 
night 0 1 2 3 4 
I 
 
Have leg jerks when you sleep 0 1 2 3 4 
J 
 
Have leg cramps when you 
sleep 0 1 2 3 4 
K 
 
Have nightmares or bad 
dreams 0 1 2 3 4 
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Instructions: Questions in the table below are about how often something wakes you 
up during your main sleep period. Circle the number that best describes how often 
you have the problem. 
 
 
12. How often do you wake up 
because of…? 
Never Rarely 
(1 day 
a 
month) 
Sometimes 
(2 – 4 days 
a month) 
Often 
(1 – 3 
days a 
week) 
Almost 
Always 
(4 or more 
days a 
week) 
A Coughing or wheezing 0 1 2 3 4 
B Stuffy nose 0 1 2 3 4 
C Sinusitis 0 1 2 3 4 
D Burping/belching 0 1 2 3 4 
E Chest pain or tightness 0 1 2 3 4 
F Shortness of breath 0 1 2 3 4 
G Sweats or hot flashes 0 1 2 3 4 
H Noise in your surroundings 0 1 2 3 4 
I 
Pain in joints, muscles, or 
back 0 1 2 3 4 
J Heartburn or indigestion 0 1 2 3 4 
K Eating a spicy meal 0 1 2 3 4 
L Leg cramps 0 1 2 3 4 
M Leg jerks 0 1 2 3 4 
N Need to go to the bathroom 0 1 2 3 4 
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Instructions: Questions 13 through 17 are about snoring and breathing when you 
sleep. When you answer these questions, think about what you know about yourself 
and what others have told you about yourself. 
 
Fill in the circle in front of the answer that is correct for you. 
 
13. Have you ever snored (now or at any time in the past)? 
 0 No 
  1 Yes 
  9 I don‟t know 
 
14. For how many years have you been snoring? 
 
 _________ (Number of years) 
 
 999 I don‟t know 
15. How often do you snore? 
  0 Never 
  1 Rarely (less than 1 night a week) 
  2 Sometimes (1 or 2 nights a week) 
  3 Often (3 to 5 nights a week) 
  4 Almost always (6 or 7 nights a week) 
  9 I don‟t know 
 
16. How loud is your snoring? 
  0 I never snore 
  1 Only slightly louder than heavy breathing 
  2 About as loud as mumbling or talking 
  3 Louder than talking 
  4 Extremely loud – can be heard through a closed door 
  9 I don‟t know 
 
17. Do you ever stop breathing during your sleep? 
  0 No 
  1 Yes 
  9 I don‟t know 
 
18. Has anyone ever told you that they saw you stop breathing during your sleep? 
  0 No 
  1 Yes 
  9 I don‟t know 
 
19. Have you ever been told by a health care provider that you have sleep apnea (a 
condition in which breathing stops briefly during sleep)? 
  0 No 
  1 Yes 
  9 I don‟t know 
 
 
Please continue on the next page 
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Instructions: The following questions are about uncomfortable feelings or sensations 
that people sometimes get in their legs. Fill in the circle in front of the answer that is 
correct for you. 
 
20. In the past year, while SITTING OR LYING DOWN, have you had any of the 
following symptoms? 
A.  An urge to move your legs   
 0 No 
   1 Yes 
   9 I don‟t know 
 
 B.  Unpleasant or uncomfortable feelings in your legs 
 0 No 
   1 Yes 
   9 I don‟t know 
 
21. How often do you get these symptoms? (Check the one best answer): 
  0 Never 
  1 Less than once a month 
  2 About once a month 
  3 2 - 4 days a month  
  4 5 - 15 days a month 
  5 Most days (16 - 23 days a month) 
 6 Daily (6 days a week or more) 
 9 I don‟t know 
 
22. How bothersome or troublesome is this symptom? (Answer based on most frequent 
symptom). Does it bother you (Check one): 
 0 Never 
  1 Hardly 
  2 A little 
  3 Moderately 
  4 A lot 
  5 Extremely 
 
23. These symptoms are most likely to occur when you are (Check the one best answer): 
 0 I don‟t have these symptoms 
  1 Resting, sitting or lying down 
  2 Exercising or just stopped exercising 
  3 Standing or walking 
  4 Having a leg cramp or “Charlie horse” 
  9 I don‟t know 
 
24. Are they worse when you are sitting or lying down than when you are moving around 
or walking? 
 0 No 
  1 Yes 
  9 I don‟t know 
 
Please continue on the next page 
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25. Do the symptoms improve if you get up and start walking? 
 0 No 
  1 Yes 
  9 I don‟t know 
 
26. What time of the day do these symptoms occur? (Check the one best answer): 
  0 I do not have these symptoms 
  1 Daytime only (before 6 PM) 
  2 Bedtime only 
  3 Evening or nighttime only (after 6 PM) 
  4 Both day and night 
 
27. Has anyone in your family had these unpleasant or uncomfortable feelings in their 
legs (e.g., grandparents, mother, father, brothers, sisters, nieces/nephews, cousins)? 
 0 No 
  1 Yes 
  9 I don‟t know 
 
28. How long have you had these uncomfortable feelings or urge to move your legs? 
 0 I do not have these uncomfortable feelings or urges to move my legs 
  1 Less than 1 year 
  2 1 – 5 years 
  3 5 – 10 years 
  4 More than 10 years 
 5 Since childhood 
 
29. Has a doctor or health care provider ever told you that you have the Restless Legs 
Syndrome? 
 0 No 
  1 Yes 
  9 I don‟t know 
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Latino Spiritual Perspective Scale  
Directions: The following questions are designed to gain an understanding of  
your spiritual beliefs and practices.  Please circle the answer that best describes 
how much you agree or disagree.  There are no right or wrong answers.  
 
1. I believe God (or a Higher Power) is loving and kind.     
Agree strongly       Agree        Agree a little      Disagree a Little        Disagree        Disagree Strongly 
          6                        5                   4                         3                             2                           1 
2. Talking every day with God or my Higher Power is important to me.  
Agree strongly       Agree        Agree a little      Disagree a Little        Disagree        Disagree Strongly 
          6                        5                   4                         3                             2                           1 
3. I feel close to the Virgin Mary.  
Agree strongly       Agree        Agree a little      Disagree a Little        Disagree        Disagree Strongly 
          6                        5                   4                         3                             2                           1 
4. My religion or spirituality guides me to do what is right.                                                                         
Agree strongly       Agree        Agree a little      Disagree a Little        Disagree        Disagree Strongly 
          6                        5                   4                         3                             2                           1 
5. I depend on God or my Higher Power to help me with my problems. 
Agree strongly       Agree        Agree a little      Disagree a Little        Disagree        Disagree Strongly 
          6                        5                   4                         3                             2                           1 
6. I feel close to Jesus.   
Agree strongly       Agree        Agree a little      Disagree a Little        Disagree        Disagree Strongly 
          6                        5                   4                         3                             2                           1 
7. My well-being is in God‟s/Higher Power‟s hands.    
 Agree strongly       Agree        Agree a little      Disagree a Little        Disagree        Disagree Strongly 
          6                        5                   4                         3                             2                           1 
8. My spirituality helps me get through bad times.                    
Agree strongly       Agree        Agree a little      Disagree a Little        Disagree        Disagree Strongly 
          6                        5                   4                         3                             2                           1  
Please list anything you would like to add about your views on spirituality.  
__________________________________________________________________
__________________________________________________________________
_____________________________________________________©Campesino 2004 
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Hospital Anxiety and 
Depression Scale (HADS)   
 
 
F
O
L
D
 H
E
R
E
 
Name: ______________________________________________________  Date: _______________  
Clinicians are aware that emotions play an important part in most illnesses. If your clinician knows about 
these feelings he or she will be able to help you more. 
This questionnaire is designed to help your clinician to know how you feel. Read each item below and 
underline the reply which comes closest to how you have been feeling in the past week. Ignore the 
numbers printed at the edge of the questionnaire. 
Don‘t take too long over your replies, your immediate reaction to each item will probably be more 
accurate than a long, thought-out response. 
F
O
L
D
 H
E
R
E
 
 
 Now check that you have answered all the questions  
    A D  
 TOTAL     
 
HADS copyright © R.P. Snaith and A.S. Zigmond, 1983, 1992, 1994.  
Record form items originally published in Acta Psychiatrica Scandinavica, 67, 361–70,  
copyright © Munksgaard International Publishers Ltd, Copenhagen, 1983. 
This edition first published in 1994 by nferNelson Publishing Company Ltd,  
414 Chiswick High Road, London W4 5TF 
GL Assessment is part of the Granada Group 
This form may not be reproduced by any means without first obtaining permission from the publisher.  
Email: permissions@gl-assessment.co.uk 
 
 
 A D   
    I feel tense or ‘wound up’ 
 3   Most of the time 
 2   A lot of the time 
 1   From time to time, occasionally 
 0   Not at all 
    I still enjoy the things I used to enjoy 
  0  Definitely as much 
  1  Not quite so much 
  2  Only a little 
  3  Hardly at all 
 
  
 I get a sort of frightened feeling as if 
something awful is about to happen 
 3   Very definitely and quite badly 
 2   Yes, but not too badly 
 1   A little, but it doesn‘t worry me 
 0   Not at all 
    I can laugh and see the funny side of things 
  0  As much as I always could 
  1  Not quite so much now 
  2  Definitely not so much now 
  3  Not at all 
    Worrying thoughts go through my mind 
 3   A great deal of the time 
 2   A lot of the time 
 1   Not too often 
 0   Very little 
    I feel cheerful 
  3  Never 
  2  Not often 
  1  Sometimes 
  0  Most of the time 
    I can sit at ease and feel relaxed 
 0   Definitely 
 1   Usually 
 2   Not often 
 3   Not at all 
  A D  
I feel as if I am slowed down     
Nearly all the time   3  
Very often   2  
Sometimes   1  
Not at all   0  
I get a sort of frightened feeling like 
‘butterflies’ in the stomach 
 
   
Not at all  0   
Occasionally  1   
Quite often  2   
Very often  3   
I have lost interest in my appearance     
Definitely   3  
I don‘t take as much care as I should   2  
I may not take quite as much care   1  
I take just as much care as ever   0  
I feel restless as if I have to be on the move     
Very much indeed  3   
Quite a lot  2   
Not very much  1   
Not at all  0   
I look forward with enjoyment to things     
As much as I ever did   0  
Rather less than I used to   1  
Definitely less than I used to   2  
Hardly at all   3  
I get sudden feelings of panic     
Very often indeed  3   
Quite often  2   
Not very often  1   
Not at all  0   
I can enjoy a good book or radio or 
television programme 
 
   
Often   0  
Sometimes   1  
Not often   2  
Very seldom   3  
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APPENDIX B  
2. SPANISH INSTRUMENT  
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Formulario Demográfico 
 
Instrucciones: Conteste las siguientes preguntas llenando los espacios vacios o 
los círculos al frente de las respuestas.  Sus datos serán completamente 
confidenciales. 
  
1. ¿Cuál es la fecha de hoy?  Mes ____ Día ____ Año _____ 
 
2. ¿Cuál es su estatura? _____ cm  
 
3. ¿Cuál es su peso? _____ kg 
 
4. ¿Cuál es su sexo?  
  1 Masculino 
  0 Femenino 
 
5. ¿Cuál es su edad?       ________ (Número de años) 
 
6. ¿Cuál es su fecha de nacimiento?  Mes ____ Día ____ Año _____ 
 
7. Presión Arterial _________________________Tomada (fecha)__________________ 
 
7. ¿En dónde nació (ciudad, estado, y país)? 
__________________________________________________  
 
8. ¿En dónde ha vivido la mayoría de su vida adulta (ciudad, estado, y país)? 
________________________ 
 
9. ¿Cuántos años de escuela ha completado? _______ (Número de años) 
 
10. ¿Qué nivel de escuela a completado?  
  0 Nunca atendí la escuela 
  1 Menos de 6 años (escuela primaria) 
  2 6 a 8 años (escuela secundaria) 
  3 9 a 11 años (escuela preparatoria) 
  4 Preparatoria o GED 
  5 Grado de Asociado o  equivalente 
  6 Licenciatura o equivalente 
  7 Maestría o equivalente 
  8 Doctorado o equivalente 
 
11. Estado Civil:  
  4 Casado/a o viviendo con pareja 
  3 Separado/a o Divorciado/a 
  2 Soltero/a 
  1 Viudo/a 
 
12.  Contándose a sí mismo/a, ¿cuántas personas viven en su casa o apartamento?  Por 
favor incluya adultos, bebés y niños/as que habitualmente viven con usted.   
Número de personas: _____________ 
 
13. ¿Cuál es su historial de fumar? 
  0 Nunca he fumado  
 1 Fumo 
  2 Antes fumaba pero ya no  
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14.  ¿Qué tipo de seguro médico tiene usted?  (Elija todo lo que se refiera a Ud.) 
  
Ninguno ……………………………………..…..…..   1 _____ 
IMSS…………………………………………….…..….   2 _____ 
ISSSTE………………………………………………....   3 _____ 
Particular, seguro médico con pago de cuota (ej. Prudencial…..  4 _____ 
PEMEX………………………………………………….   5 _____ 
SEDENA…………………….………………………….   6 _____ 
Seguro Popular………………………………………..   7 _____ 
 
  
15.  ¿Cuál fue su ingreso total en el mes pasado (considerando todas las entradas como 
por ejemplo el dinero que recibe del gobierno para sus hijos, por estar desempleado, o 
por estar deshabilitado o del seguro social).  Recuerde que sus respuestas son 
confidenciales. 
 
Por favor marque con una X su respuesta a la siguiente información ($54.47): 
 
Ninguno………… ……………………………………………… 1 _____ 
 
Menos de 1SM ($1661.335)…………………………………… 2 _____ 
Entre 1SM y menos de 2SM 
($1661.335- 3322.67)………...…………………………………… 3 _____ 
Entre 2SM y menos de 3SM 
($3322.67-4984.005).………………….……..…………………… 4 _____ 
Entre 3SM y menos de 4SM 
($4984.005-6645.34).………………….……..…………………… 5 _____ 
Entre 4SM y menos de 5SM 
($6645.34-8306.675).………………….……..…………………… 6 _____ 
5SM o más 
($8306.675- más)…………………………..….………….……….. 7 _____ 
 
16. ¿Cuál es su religión? 
 Católica  1_______ 
 Cristiana  2_______ 
 Testigos de Jehová 3_______ 
 Judía   4_______ 
 Budista  5_______ 
 Otro_____________ 6_______ 
 
17. ¿Cuántas personas son en su familia?  
En qué posición se encuentra usted? 
 
18. ¿A qué se dedica? 
¿continúa trabajando en lo mismo?   Si_____1 
     No____2 
   No igual que antes____3  
 
19. ¿Cuántas veces al mes viene a esta clínica u hospital debido a su 
tratamiento?___________ 
 
20. ¿Cuánto dinero gasta en promedio cada vez que viene a esta clínica u 
hospital?__________ 
 
21. Pierde usted el día de trabajo, o su acompañante cada vez que viene? 
118 
Formulario Médico 
 
20. ¿Cuál es la enfermedad que causó su insuficiencia renal? 
Diabetes Mellitus   1___ 
Hipertensión    2___ 
Riñones poliquísticos   3___ 
Glomerulonefritis   4___ 
Otro _____________  5___ 
Desconoce    6___ 
 
21. ¿Cuál es el tipo de tratamiento de diálisis que ha tenido los últimos seis 
meses?  
 
Diálisis peritoneal continua ambulatoria   (DPCA) 1____ 
Diálisis peritoneal automatizada    2____ 
Hemodiálisis      3____ 
 
22. Si tiene diálisis peritoneal, 
 
¿Cuántos cambios se hace por día?   De uno a dos _____1 
       De 3 a 4         _____2 
       De 5 a 6         _____3 
       No aplica        _____4 (DPA)  
 
¿Cómo se aplica el tratamiento generalmente? No. De bolsas ____2000ml____1 
              5000ml____2 
 
      Concentración  1.5%___ 
         2.5%___ 
         4.25%___ 
 
¿Qué tipo de catéter tiene? 
                    Tenckhoff ____1 
        Cola de cochino ____2 
        Cuello de cisne ____3 
        Otro  ____4 
        Desconoce ____5 
 
¿Desde hace cuánto le instalaron el catéter?  Hace menos de 1 año   ____1 
       De 1 año a 2 años ____2 
       De 3 a 5 años  ____3 
       Más de 5 años  ____4 
 
¿Cuándo le cambiaron su línea de transferencia? 
Hace menos de 6 meses ___1 
   Hace más de 6 meses              ___2 
 
23. Si tiene hemodiálisis, 
 
1. ¿Cuál es su horario de tratamiento?_____________  
Mañana____1 
 Tarde  ____2 
 Noche   ____3 
 Variable____4 
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2. ¿Cuánto tiempo espera antes de la diálisis?______ 
 
3. ¿Cuánto tiempo dura conectado a la máquina de hemodiálisis?_______  
 Más de 4 horas____1 
 Entre 3 y 4 hrs. ____2 
 Menos de 3 hrs.____3 
 
4. ¿Cuántas veces por semana recibe el tratamiento?     
Una _____1 
 Dos _____2 
 Tres _____3 
 Cuatro _____4 
 Cinco o más _____5 
 
5. ¿Cuántas veces estuvo hospitalizado en este último año?     
Una  _____1 
 Dos  _____2 
 Tres  _____3 
 Cuatro   _____4 
 Cinco o más _____5 
 
    6. ¿Cuánto tiempo duró hospitalizado la última vez? 
  Tres días o menos _____1 
     De 4 a 10 días  _____2 
  De 11 a 15 días  _____3 
  De 15 a 30 días  _____4 
  Más de 1 mes  _____5 
  
    7. ¿Cuál fue el motivo de su hospitalización?___________________________ 
 
 
24. Si usted toma anti-hipertensivos, cuántos tipos toma? 
1_____ 
2_____ 
3_____ 
4_____ 
 
25. ¿Cuándo fue la visita domiciliaria más reciente que tuvo por parte del equipo 
de salud? 
Hace menos de un mes  _____1 
Hace más de un mes  _____2 
Hace más de tres meses _____3 
Hace más de seis meses _____4 
 
26. ¿Quién fue el que lo visitó? 
Médico   _______1 
Enfermera(o)  _______2 
Trabajador social _______3 
Otro__________ _______4 
 
27. ¿Cuándo tuvo su última consulta médica con el especialista (nefrólogo)? 
Hace menos de un mes  _____1 
Hace más de un mes  _____2 
Hace más de tres meses _____3 
Hace más de seis meses _____4 
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28. ¿Tiene un cuidador principal?   Si_____1  
No____2 
 
29. ¿Cuál es su parentesco con el cuidador? 
Familiar (hijo)   _____1 
Familiar (esposo)  _____2 
Familiar (padre)   _____3 
Familiar (hermano)  _____4 
Familiar (otro_____)  _____5 
No es familiar   _____6 
 
 
30. ¿Quién le hace las diálisis? 
Familiar (hijo)   _____1 
Familiar (esposo)  _____2 
Familiar (padre)   _____3 
Familiar (hermano)  _____4 
Familiar (otro_____)  _____5 
No es familiar   _____6 
 
31. ¿Recibió capacitación?   Si_____1 
No____2 
 
32. ¿Dónde la recibió? ______________________________ 
 
33. ¿Hace cuánto tiempo?  Menos de tres meses _____1 
Tres a 6 meses  _____2 
6 meses a 1 año _____3 
Más de 1 año  _____4 
Más de 3 años  _____5 
 
34. ¿Qué tipo de insulina utiliza? 
NPH  ________1 
Acción lenta ________2 
Acción rápida    ________3 
No utiliza ________4 
 
35. ¿Por qué vía se aplica la insulina? 
Intraperitoneal _______1 
Subcutánea ______2 
 
36. ¿Utiliza usted eritropoyetina regularmente? 
Si_____1 
No____2 
 
37. ¿Cuándo fue la última vez que se la aplicaron?_________________ 
 
38. Cifras de laboratorio recientes: 19.1 Hemoglobina________.  
19.2 Albúmina_______. 19.3 Creatinina_______.19.4 Urea_______. 19.5 
BUN______. 
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Uso de Medicina Alternativa Complementaria 
                      
8. Ha utilizado alguna vez una terapia o remedio tradicional como los 
siguientes? 
Acupunctura     ______1 
Ayurveda     ______2 
Biofeedback     ______3 
Terapia de Chelación    ______4 
Qiropráctica     ______5   Comentarios_______ 
Terapia de Energía curativa    ______6 _____________ 
Hipnosis     ______7 _____________ 
Masajes     ______8 
Naturopatía     ______9 
Curanderos tradicionales   _____10 
Terapias de Movimiento                _____11  
Herbolaria     _____12  
Uso de suplementos no-vitaminicos  _____13 
Vitaminas y minerales    _____14 
Homeopatía      _____15 
Dietas especiales     _____16 
Yoga/tai chi/qi gong     _____17 
Técnicas de relajación     _____18 
Oración o rezo para la salud   _____19 
Brujería (barrido)    _____20 
Otros _______________   _____21 
 
9. ¿Cuáles ha utilizado en los pasados 12 meses? 
 
10. ¿En cuántas ocasiones ha visitado a la persona que le proporciona esta 
terapia? 
 
Sólo 1 vez   ____1 
Menos de 5 veces ____2 
De 5 a 15 veces ____3 
Más de 15 veces ____4 
 
11. ¿Para qué afección consultó a estas personas? ____________ 
 relacionado a IRC______1 
No relacionado IRC_____2 
 
12. ¿Recibió y tomó algún tipo de tratamiento recetado por estas personas?       
Si________1 
     No________2 
 Especifique_______________________________________________________ 
 
13. ¿Considera que el tratamiento recibido fue efectivo?   
 Si_____1 
No____2 
 ¿por qué?________________________________________________________ 
 ________________________________________________________________ 
 
14. ¿Se ha automedicado alguna vez?       
 Si_____1 
No____2 
 ¿por qué?________________________________________________________  
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SHHS Encuesta de los Hábitos del Sueño-Español  
                          Short Form Revised (S-SHQ-r) 
 
 
 
 
 
Instrucciones: Llene la respuesta correcta para usted en la pregunta 1.  
 
1. ¿Cuál es su horario de trabajo? 
  0 Yo no trabajo fuera del hogar 
  1 Trabajo días 
  2 Trabajo noches 
  3 Mi horario de trabajo cambia regularmente de día a noche 
 
Instrucciones: Muchas personas duermen por la noche, pero muchas personas trabajan de 
noche y duermen durante el día. Su periodo de sueño principal es la hora del día o noche 
cuando duerme por más tiempo. Piense en su periodo de sueño principal cuando conteste las 
preguntas en esta encuesta.  Escriba un número para contestar las preguntas 2, 3, y 4. 
  
2. ¿Usualmente cuantos minutos le toma para dormirse a la hora de acostarse? 
    
 _____ _____ (Número de minutos) 
 
3. ¿Usualmente cuantas horas duerme en la noche entre semana o los días que trabaja? 
 
 _____ _____ (Número de horas) 
 
4. ¿Usualmente cuantas horas duerme en la noche los fines de semana o los días que no trabaja? 
 
 _____ _____ (Número de horas) 
 
 
Instrucciones: Llene el circulo correcto para usted en la pregunta 5. 
  
5. ¿Trata de hacer tiempo en su horario para una siesta?  
  0 Nunca o raramente  
  1 A veces 
  2 A menudo  
  3 Todos los días o casi todos los días 
 
Instrucciones: Escriba un número en el espacio para contestar la pregunta 6. 
 
6. ¿Cuándo toma una siesta, por cuánto tiempo duerme? 
 
 __________ (Número de minutos) 
 
  0 Nunca o muy raro tomo siestas  
Sleep 
Heart 
Health 
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7. ¿Cuándo toma una siesta, cuáles son sus razones para toma una siesta regularmente en la tarde? 
 (Marque todas las que apliquen): 
 
       A.  1 Si     o     0 No No duermo lo suficiente en la noche. 
 
       B.  1 Si     o     0 No Tomo una siesta a causa de una enfermedad o condición    
 
                                                          médica. 
 
       C.  1 Si     o     0 No Tomo una siesta porque me hace sentir recuperado en general. 
 
       D.  1 Si     o     0 No Otra razón (por favor explique). 
 
__________________________________________________________________ 
 
 
Instrucciones: Las Preguntas 8, 9, y 10 se refieren a la calidad de su sueño.  Marque el 
circulo al número que corresponde.  
8. ¿En general cómo calificaría la calidad de su sueño? 
 
  0 Ligero (Me despierto muy fácilmente) 
  1 Algo ligero (Me despierto fácilmente) 
  2 Moderado (A veces me despierto pero no fácilmente) 
  3 Algo profundo (Duermo bien) 
  4 Profundo (Duermo muy bien) 
 
9. ¿En general cómo calificaría la calidad del tiempo de su sueño? 
 
 0 Corto (Siento que me acabo de ir a dormir aunque haya dormido 8 horas) 
 1 Algo corto (Siento como que he dormido 2 horas aunque haya dormido 8 horas) 
 2 Moderado (Siento como que he dormido 4 horas aunque haya dormido 8 horas) 
 3 Algo Largo (Siento como que he dormido 6 horas aunque haya dormido 8 horas) 
 4 Largo (Siento como que dormí 8 horas o más aunque haya dormido 8 horas) 
 
10. ¿En general cómo calificaría la calidad de su sueño? 
 
 0 Inquieto (Me muevo mucho y no descanso) 
 1 Algo inquieto (Me muevo un poco y no descanso) 
 2 Moderado (Me muevo muy poco y descanso poco) 
 3 Algo Descansado (No me muevo en la noche y tengo un sueño descansado)  
 4 Tranquilo (No me muevo en la noche y duermo bien) 
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Instrucciones: Las siguientes preguntas se refieren a que tan seguido tiene problemas de 
sueño. Marque con un círculo al número que corresponde para las preguntas (A-K). 
 
11. Por favor indique que tan 
seguido le ocurren las 
siguientes cosas   
(Marque solamente una 
caja por cada pregunta 
de la A – K): 
Nunca 
(0) 
Raramente 
(1 vez cada 
mes o menos) 
A veces 
(2 – 4 
veces 
cada 
mes) 
A menudo 
(5 – 15 
veces cada 
mes) 
Casi 
siempre 
(16 – 30 
veces 
cada 
mes) 
A Tiene dificultad en 
dormirse 0 1 2 3 4 
B Se despierta durante la 
noche y después tiene 
dificultad en quedarse 
dormido  0 1 2 3 4 
C Se despierta muy 
temprano en la mañana y 
no puede volver a dormir  0 1 2 3 4 
D Se siente cansado durante 
el día no importa cuántas 
horas haya dormido  0 1 2 3 4 
E Se siente  excesivamente 
cansado durante el día  0 1 2 3 4 
F No duerme lo suficiente 0 1 2 3 4 
G Toma pastillas para 
dormir u otro 
medicamento para 
ayudarle a dormir  0 1 2 3 4 
H Congestión nasal, 
obstrucción, o desecho 
nasal en la noche 0 1 2 3 4 
I Movimientos bruscos 
(involuntarios) en las 
piernas 0 1 2 3 4 
J Calambres en las piernas 0 1 2 3 4 
K Pesadillas o malos sueños 0 1 2 3 4 
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Instrucciones: Las siguientes preguntas se refieren a que tan seguido algo lo despierta 
mientras duerme. Marque con un círculo al número que corresponde para las preguntas (A-
L). 
 
12. ¿En este año pasado, 
que tan seguido ha sido 
usted despertado por las 
siguientes cosas?  
(Marque solamente una caja por 
cada pregunta de la A – M): 
Nunca 
(0) 
Raramen
te 
(1 vez 
cada mes 
o menos) 
A veces 
(2 – 4 
veces 
cada mes) 
A 
menudo 
(5 – 15 
veces 
cada 
mes) 
Casi 
siempre 
(16 – 30 
veces 
cada 
mes) 
A Tos o silbido (resuello) 0 1 2 3 4 
B 
Nariz tapada 
(mormada/o) 0 1 2 3 4 
C Sinusitis 0 1 2 3 4 
D Eructando (repitiendo)  0 1 2 3 4 
E 
Dolor o presión en el 
pecho  0 1 2 3 4 
F Falta de respiración  0 1 2 3 4 
G 
Bochornos o sofocos de 
calor (sudores) 0 1 2 3 4 
H 
Ruido en sus 
alrededores  0 1 2 3 4 
I 
Dolor en sus 
coyunturas, músculos o 
espalda  0 1 2 3 4 
J 
Acidez estomacal o 
indigestión  0 1 2 3 4 
K 
Después de una comida 
picante  0 1 2 3 4 
L 
Calambres o 
movimientos 
(involuntarios)  en las 
piernas.   0 1 2 3 4 
M Necesidad de ir al baño  0 1 2 3 4 
 
 
Instrucciones: Las siguientes preguntas se refieren al roncar y respirar mientras duerme.  
Para contestar estas preguntas por favor considere lo que otros le han dicho y lo que usted 
sabe de usted mismo.  Marque el círculo al número que corresponde. 
 
13. ¿Ha usted roncado alguna vez (ahora o en el pasado)? 
 0 No 
  1 Si 
  9 Ya no ronco 
 
14. ¿Por cuántos años ha estado roncado? 
 __________ (Número de años)                     
 999 No sé 
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15. ¿Qué tan seguido ronca?  (Marque una)  
  0 Nunca 
  1 Raramente—menos de una noche por semana  
  2 A veces—1 o 2 noches por semana 
  3 Frecuentemente—3 a 5 noches por semana 
  4 Siempre o casi siempre—6 o 7 noches por semana 
 9 No sé 
 
16. ¿Qué tan fuerte ronca?  (Marque una) 
  0 Nunca Ronco  
  1 Un poco más alto que una respiración pesada  
  2 Casi igual de alto que al murmurar o hablar calladito  
  3 Más fuerte que hablar 
  4 Extremadamente alto—se puede oír con la puerta cerrada 
 9 No sé 
 
17. ¿Ha habido veces que ha dejado de respirar mientras duerme? 
  0 No 
  1 Si 
 9 No sé 
 
18. ¿Alguna vez le han dicho que lo vieron dejar de respirar mientras dormía? 
  0 No 
  1 Si 
 9 No sé 
 
19. ¿Alguna vez le ha dicho un doctor que tiene apnea (una condición en la cual deja de respirar 
brevemente mientras duerme)? 
  0 No 
  1 Si 
 9 No sé 
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Instrucciones: Las siguientes preguntas se refieren a sensaciones incomodas que la gente 
siente en las piernas que son difícil de describir.  Marque el círculo que más le corresponda.  
 
20. ¿En este año pasado, ha estado sentado o acostado, tuvo alguno de los siguientes síntomas?  
 
 A. Urgencia/necesidad de mover sus piernas 
 0 No 
   1 Si 
   9 No sé 
  
 B. Una sensación desagradable/incomoda en las piernas 
 0 No 
   1 Si 
   9 No sé 
 
21. ¿Que tan frecuente tiene estos síntomas? (Marque la mejor respuesta.)  
  0 Nunca 
  1 Menos de una vez al mes 
  2 Aproximadamente una vez por mes  
  3 2 - 4 días al mes  
  4 5 - 15 días al mes 
  5 Casi todos los días (16 - 23 días al mes) 
 6 Diariamente (6 días a la semana o más) 
 9 No sé  
 
22. ¿Qué tan desagradable o molesto es este síntoma? (Conteste la pregunta basándose en el 
síntoma más frecuente) Le molesta (marque la mejor respuesta): 
 0 Nunca 
  1 Casi nada 
  2 Un poco 
  3 Moderadamente 
  4 Mucho 
  5 Extremadamente 
 
23. Estos síntomas suelen suceder cuando usted está (Marque la mejor respuesta): 
 0 No tengo estos síntomas 
  1 Descansando, sentado, o acostado 
  2 Haciendo ejercicio o terminando de hacer ejercicio 
  3 Parado o caminando 
  4 Teniendo un calambre en la pierna 
  9 No sé 
 
24. ¿Son los síntomas peores cuando está sentado o acostado en comparación a cuando se está 
moviendo o caminando?   
 0 No 
  1 Si 
  9 No sé 
 
25. ¿Mejoran los síntomas si se levanta y empieza a caminar? 
 0 No 
  1 Si 
  9 No sé 
 
26. ¿A qué hora del día ocurren los síntomas?  (Marque la mejor respuesta): 
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  0 No tengo incomodidad o ganas de mover mis piernas 
  1 Únicamente durante el día (antes de las 6 PM) 
  2 Únicamente a la hora de dormir 
  3 Únicamente en la noche (después de las 6 PM) 
  4 Únicamente en la noche (después de las 6 PM) 
  5 En el día y en la noche  
  
27. ¿Hay alguien más en su familia que sufre de una sensación desagradable o incomoda en las  
Piernas (como abuelo/as, madre, padre, hermano/as, sobrino/as, nieto/as)? 
  0 No 
  1 Si 
  9 No sé 
 
28. ¿Por cuánto tiempo a tenido la sensación incomoda o ganas de mover sus piernas? 
  0 No tengo incomodidad o las ganas de mover mis piernas 
  1 Menos de 1 año 
  2 1 – 5 años 
  3 5 – 10 años 
  4 Más de 10 años 
 5 Desde la infancia 
 
29. ¿Le ha dicho un doctor que tiene el síndrome de las piernas inquietas (Restless Leg 
Síndrome)?  
 0 No 
  1 Si 
  9 No sé  
 
Instrucciones: Las siguientes preguntas se refieren a la hora y lugares donde usted siente que 
se quiere dormir.  Marque con un círculo el número que corresponde para cada situación de 
la (A-J).  Si usted nunca o raramente esta en esta situación, por favor de marcar su mejor 
respuesta 
 
30. ¿Cuál es la posibilidad de que usted cabecea 
(no únicamente ―sentirse cansado‖)? 
(Marque solamente una caja por cada posibilidad de la A – J): 
No hay 
posibili
dad 
Una leve 
posibilida
d 
Una 
posibilidad 
moderada 
Una gran 
posibilida
d 
A Sentado y leyendo 0 1 2 3 
B Mirando la televisión 0 1 2 3 
C 
Sentado inactivo en un lugar público (por 
ejemplo en el cine o en una junta) 0 1 2 3 
D 
Sentado en un auto como pasajero por una 
hora sin descanso 0 1 2 3 
E 
Acostado y descansando en la tarde si las 
circunstancias lo permiten 0 1 2 3 
F Sentado y platicando con alguien 0 1 2 3 
G 
Sentado tranquilamente después de un 
almuerzo y sin haber bebido alcohol 0 1 2 3 
H 
En el auto, mientras esta estacionado en el 
tráfico por unos minutos 0 1 2 3 
I En la mesa mientras cena 0 1 2 3 
J Mientras conduce su auto 0 1 2 3 
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CUESTIONARIO DE SALUD SF-36 VERSIÓN ESPAÑOLA 1.4 (junio de 1999) 
 
INSTRUCCIONES: Las preguntas que siguen se refieren a lo que usted piensa sobre su salud. Sus 
respuestas permitirán saber cómo se encuentra usted y hasta qué punto es capaz de hacer sus actividades 
habituales. Conteste cada pregunta tal como se indica. Si no está seguro/a de cómo responder a una pregunta, 
por favor conteste lo que le parezca más cierto. 
            Copyright  1995 Medical Outcomes Trust  All rights reserved.(Versión 1.4, Junio 1.999) 
                Correspondencia: Dr. Jordi Alonso. Unidad de Investigación en Servicios Sanitarios I.M.I.M. 
Doctor Aiguader, 80.E- 08003 Barcelona, España 
Tel. + 34 3 221 10 09 Fax. + 34 3 221 32 37.E-mail: pbarbas@imim.es 
MARQUE UNA SOLA RESPUESTA 
 
1. En general, usted diría que su salud es: 
1 � Excelente.    2 � Muy buena.     3 � Buena.     4 � Regular.     5 � Mala. 
 
2. ¿Cómo diría que es su salud actual, comparada con la de hace un año? 
1 � Mucho mejor ahora que hace un año.    2 � Algo mejor ahora que hace un año 
3 � Más o menos igual que hace un año.     4 � Algo peor ahora que hace un año 
5 � Mucho peor ahora que hace un año 
 
LAS SIGUIENTES PREGUNTAS SE REFIEREN A ACTIVIDADES O COSAS QUE USTED 
PODRÍA HACER EN UN DÍA NORMAL. 
 
3. Su salud actual, ¿le limita para hacer esfuerzos intensos, tales como correr, levantar objetos 
pesados, o participar en deportes agotadores? 
1 � Sí, me limita mucho         2 � Sí, me limita un poco      3 � No, no me limita nada 
 
4. Su salud actual, ¿le limita para hacer esfuerzos moderados, como mover una mesa, pasar la 
aspiradora, jugar a los bolos o caminar más de una hora? 
1 � Sí, me limita mucho         2 � Sí, me limita un poco      3 � No, no me limita nada 
 
5. Su salud actual, ¿le limita para coger o llevar la bolsa de las compras? 
1 � Sí, me limita mucho         2 � Sí, me limita un poco      3 � No, no me limita nada 
 
6. Su salud actual, ¿le limita para subir varios pisos por la escalera? 
1 � Sí, me limita mucho         2 � Sí, me limita un poco      3 � No, no me limita nada 
 
7. Su salud actual, ¿le limita para subir un solo piso por la escalera? 
1 � Sí, me limita mucho         2 � Sí, me limita un poco      3 � No, no me limita nada 
 
8. Su salud actual, ¿le limita para agacharse o arrodillarse? 
1 � Sí, me limita mucho         2 � Sí, me limita un poco      3 � No, no me limita nada 
 
9. Su salud actual, ¿le limita para caminar un kilómetro o más? 
1 � Sí, me limita mucho         2 � Sí, me limita un poco      3 � No, no me limita nada 
 
10. Su salud actual, ¿le limita para caminar varias manzanas (varios centenares de metros)? 
1 � Sí, me limita mucho         2 � Sí, me limita un poco      3 � No, no me limita nada 
 
11. Su salud actual, ¿le limita para caminar una sola manzana (unos 100 metros)? 
1 � Sí, me limita mucho         2 � Sí, me limita un poco      3 � No, no me limita nada 
 
12. Su salud actual, ¿le limita para bañarse o vestirse por sí mismo? 
1 � Sí, me limita mucho         2 � Sí, me limita un poco      3 � No, no me limita nada 
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LAS SIGUIENTES PREGUNTAS SE REFIEREN A PROBLEMAS EN SU TRABAJO O EN 
SUS ACTIVIDADES COTIDIANAS. 
 
13. Durante las 4 últimas semanas, ¿tuvo que reducir el tiempo dedicado al trabajo o a sus 
actividades cotidianas, a causa de su salud física? 
1 � Sí             2 � No 
 
14. Durante las 4 últimas semanas, ¿hizo menos de lo que hubiera querido hacer, a causa de su 
salud física? 1 � Sí            2 � No 
 
15. Durante las 4 últimas semanas, ¿tuvo que dejar de hacer algunas tareas en su trabajo o en 
sus actividades cotidianas, a causa de su salud física? 
1 � Sí           2 � No 
 
16. Durante las 4 últimas semanas, ¿tuvo dificultad para hacer su trabajo o sus actividades 
cotidianas (por ejemplo, le costó más de lo normal), a causa de su salud física?  
 1 � Sí             2 � No 
 
17. Durante las 4 últimas semanas, ¿tuvo que reducir el tiempo dedicado al trabajo o a sus 
actividades cotidianas, a causa de algún problema emocional (como estar triste, deprimido, o 
nervioso? 1 � Sí             2 � No 
 
18. Durante las 4 últimas semanas, ¿hizo menos de lo que hubiera querido hacer, a causa de algún 
problema emocional (como estar triste, deprimido, o nervioso)? 
1 � Sí             2 � No 
 
19. Durante las 4 últimas semanas, ¿no hizo su trabajo o sus actividades cotidianas tan 
cuidadosamente como de costumbre, a causa de algún problema emocional (como estar triste, 
deprimido, o nervioso)? 1 � Sí            2 � No 
 
20. Durante las 4 últimas semanas, ¿hasta qué punto su salud física o los problemas emocionales 
han dificultado sus actividades sociales habituales con la familia, los amigos, los vecinos u otras 
personas? 
1 � Nada.    2 � Un poco.     3 � Regular.     4 � Bastante.     5 � Mucho. 
 
21. ¿Tuvo dolor en alguna parte del cuerpo durante las 4 últimas semanas? 
1 � No, ninguno           
2 � Sí, muy poco 
3 � Sí, un poco 
4 � Sí, moderado 
5 � Sí, mucho 
6 � Sí, muchísimo 
 
22. Durante las 4 últimas semanas, ¿hasta qué punto el dolor le ha dificultado su trabajo habitual 
(incluido el trabajo fuera de casa y las tareas domésticas)? 
1 � Nada 
2 � Un poco 
3 � Regular 
4 � Bastante 
5 � Mucho 
 
LAS PREGUNTAS QUE SIGUEN SE REFIEREN A CÓMO SE HA SENTIDO Y CÓMO LE HAN IDO 
LAS COSAS DURANTE LAS 4 ÚLTIMAS SEMANAS. EN CADA PREGUNTA RESPONDA LO QUE 
SE PAREZCA MÁS A CÓMO SE HA SENTIDO USTED. 
 
131 
23. Durante las 4 últimas semanas, ¿cuánto tiempo se sintió lleno de vitalidad? 
1 � Siempre 
2 � Casi siempre 
3 � Muchas veces 
4 � Algunas veces 
5 � Sólo alguna vez 
6 � Nunca 
 
24. Durante las 4 últimas semanas, ¿cuánto tiempo estuvo muy nervioso? 
1 � Siempre 
2 � Casi siempre 
3 � Muchas veces 
4 � Algunas veces 
5 � Sólo alguna vez 
6 � Nunca 
 
25. Durante las 4 últimas semanas, ¿cuánto tiempo se sintió tan bajo de moral que nada podía 
animarle?  1 � Siempre 
2 � Casi siempre 
3 � Muchas veces 
4 � Algunas veces 
5 � Sólo alguna vez 
6 � Nunca 
26. Durante las 4 últimas semanas, ¿cuánto tiempo se sintió calmado y tranquilo? 
1 � Siempre 
2 � Casi siempre 
3 � Muchas veces 
4 � Algunas veces 
5 � Sólo alguna vez 
6 � Nunca 
 
27. Durante las 4 últimas semanas, ¿cuánto tiempo tuvo mucha energía? 
1 � Siempre 
2 � Casi siempre 
3 � Muchas veces 
4 � Algunas veces 
5 � Sólo alguna vez 
6 � Nunca 
 
28. Durante las 4 últimas semanas, ¿cuánto tiempo se sintió desanimado y triste? 
1 � Siempre 
2 � Casi siempre 
3 � Muchas veces 
4 � Algunas veces 
5 � Sólo alguna vez 
6 � Nunca 
 
29. Durante las 4 últimas semanas, ¿cuánto tiempo se sintió agotado? 
1 � Siempre 
2 � Casi siempre 
3 � Muchas veces 
4 � Algunas veces 
5 � Sólo alguna vez 
6 � Nunca 
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30. Durante las 4 últimas semanas, ¿cuánto tiempo se sintió feliz? 
1 � Siempre 
2 � Casi siempre 
3 � Muchas veces 
4 � Algunas veces 
5 � Sólo alguna vez 
6 � Nunca 
 
31. Durante las 4 últimas semanas, ¿cuánto tiempo se sintió cansado? 
1 � Siempre 
2 � Casi siempre 
3 � Muchas veces 
4 � Algunas veces 
5 � Sólo alguna vez 
6 � Nunca 
 
32. Durante las 4 últimas semanas, ¿con qué frecuencia la salud física o los problemas 
emocionales le han dificultado sus actividades sociales (como visitar a los amigos o familiares)? 
   1 � Siempre 
2 � Casi siempre 
3 � Algunas veces 
4 � Sólo alguna vez 
5 � Nunca 
 
POR FAVOR, DIGA SI LE PARECE CIERTA O FALSA CADA UNA DE LAS SIGUIENTES 
FRASES. 
 
33. Creo que me pongo enfermo más fácilmente que otras personas. 
1 � Totalmente cierta 
2 � Bastante cierta 
3 � No lo sé 
4 � Bastante falsa 
5 � Totalmente falsa 
 
34. Estoy tan sano como cualquiera. 
1 � Totalmente cierta 
2 � Bastante cierta 
3 � No lo sé 
4 � Bastante falsa 
5 � Totalmente falsa 
 
35. Creo que mi salud va a empeorar. 
1 � Totalmente cierta 
2 � Bastante cierta 
3 � No lo sé 
4 � Bastante falsa 
5 � Totalmente falsa 
 
36. Mi salud es excelente. 
1 � Totalmente cierta 
2 � Bastante cierta 
3 � No lo sé 
4 � Bastante falsa 
5 � Totalmente falsa 
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ESCALA DE LA PERSPECTIVA ESPIRITUAL LATINA 
 
Instrucciones: Las siguientes preguntas han sido preparadas para entender sus 
creencias y prácticas espirituales.  Por favor, marque la respuesta que Ud. Piensa que 
más refleja su opinión.  No hay respuesta que sea correcta o incorrecta. 
 
1. Creo en Dios (o un Poder Superior) que es amable y cariñoso.  
 
Estoy muy        Estoy de        Estoy un poco        Estoy un poco           Estoy en      Estoy fuertemente 
de acuerdo        acuerdo         de  acuerdo            en desacuerdo         desacuerdo           en  desacuerdo 
       6          5                  4                    3                          2      1 
 
2. Para mí es importante hablar con Dios o mi Poder Superior todos los días. 
 
Estoy muy        Estoy de        Estoy un poco        Estoy un poco           Estoy en      Estoy fuertemente 
de acuerdo        acuerdo         de  acuerdo            en desacuerdo         desacuerdo           en  desacuerdo 
       6          5                  4                    3                          2      1 
 
3. Me siento cerca a la Virgen María. 
 
Estoy muy        Estoy de        Estoy un poco        Estoy un poco           Estoy en      Estoy fuertemente 
de acuerdo        acuerdo         de  acuerdo            en desacuerdo         desacuerdo           en  desacuerdo 
       6          5                  4                    3                          2      1 
 
4. Mi religión o espiritualidad me guía a hacer lo que es correcto. 
 
Estoy muy        Estoy de        Estoy un poco        Estoy un poco           Estoy en      Estoy fuertemente 
de acuerdo        acuerdo         de  acuerdo            en desacuerdo         desacuerdo           en  desacuerdo 
       6          5                  4                    3                          2      1 
 
5.   Yo dependo de Dios o mi Poder Superior para ayudarme con mis problemas. 
 
Estoy muy        Estoy de        Estoy un poco        Estoy un poco           Estoy en      Estoy fuertemente 
de acuerdo        acuerdo         de  acuerdo            en desacuerdo         desacuerdo           en  desacuerdo 
       6          5                  4                    3                          2      1 
 
6. Me siento cerca de Jesús. 
 
Estoy muy        Estoy de        Estoy un poco        Estoy un poco           Estoy en      Estoy fuertemente 
de acuerdo        acuerdo         de  acuerdo            en desacuerdo         desacuerdo           en  desacuerdo 
       6          5                  4                    3                          2      1 
 
7. Mi bienestar está en las manos de Dios/Poder Superior. 
 
Estoy muy        Estoy de        Estoy un poco        Estoy un poco           Estoy en      Estoy fuertemente 
de acuerdo        acuerdo         de  acuerdo            en desacuerdo         desacuerdo           en  desacuerdo 
       6          5                  4                    3                          2      1 
 
8. Mi espiritualidad me ayuda durante tiempos malos. 
 
Estoy muy        Estoy de        Estoy un poco        Estoy un poco           Estoy en      Estoy fuertemente 
de acuerdo        acuerdo         de  acuerdo            en desacuerdo         desacuerdo           en  desacuerdo 
       6          5                  4                    3                          2      1 
 
Por favor, si desea, incluya comentarios adicionales sobre su espiritualidad. 
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
______________________________________________________ 
                                                                                                      © Campesino  2004 
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Cuestionario de ansiedad y 
depresión en hospitales y centros 
de atención médica (HADS) 
 
 
D
O
B
L
A
R
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Q
U
Í
 
Nombre:  ____________________________________________________  Fecha:  _____________  
Los médicos están conscientes del papel importante que desempeñan las emociones en la mayoría de las 
enfermedades. Si su médico conoce estas emociones podrá ayudarle más. 
Este cuestionario está diseñado para ayudar a que su médico sepa cómo se siente usted. Lea cada una de 
las preguntas escritas abajo y subraye la respuesta que refleja de mejor manera cómo se ha sentido en los 
últimos 7 días. Ignore los números impresos en los márgenes del cuestionario. 
No se tarde mucho en dar la respuesta, su reacción inmediata a cada una de las preguntas probablemente 
sea más exacta que una respuesta que haya sido muy pensada. 
D
O
B
L
A
R
 A
Q
U
Í
 
 
 Ahora verifique que ha contestado todas las preguntas  
    A D  
 TOTAL     
 
HADS derechos de autor © R.P. Snaith y A.S. Zigmond, 1983, 1992, 1994.  
Las preguntas de este cuestionario se publicaron en su forma original en Acta Psychiatrica Scandinavica, 67, 361–70,  
derechos de autor © Munksgaard International Publishers Ltd, Copenhagen, 1983. 
Ésta edición se publicó por primera vez en 1994 por nferNelson Publishing Company Ltd,  
 414 Chiswick High Road, London W4 5TF 
GL Assessment es una división del Grupo Granada 
Éste cuestionario no puede ser reproducido por ningún medio sin tener el permiso del editor. 
 Email: permissions@gl-assessment.co.uk 
 
 
 A D   
    Me siento tenso/a o nervioso/a 
 3   La mayor parte del tiempo 
 2   Mucho tiempo 
 1   De vez en cuando, ocasionalmente 
 0   Nunca 
    Aún disfruto las cosas que solía disfrutar 
  0  Definitivamente igual que antes 
  1  No tanto como antes 
  2  Sólo un poco 
  3  Casi nada 
 
  
 
Tengo una especie de miedo, como si algo muy 
malo fuera a pasar 
 3   Muy definitivamente y muy intenso 
 2   Sí, pero no tan intenso 
 1   Un poco pero no me preocupa 
 0   Nunca 
    Me puedo reír y ver el lado gracioso de las cosas 
  0  Tanto como siempre 
  1  No tanto ahora 
  2  Definitivamente mucho menos ahora 
  3  Nunca 
    Vienen a mi mente pensamientos de preocupación 
 3   La mayor parte del tiempo 
 2   Mucho tiempo 
 1   No muy seguido 
 0   Muy poco 
    Me siento contento/a 
  3  Nunca 
  2  No muy seguido 
  1  Algunas veces 
  0  La mayor parte del tiempo 
    Me puedo sentar en calma y sentirme relajado/a 
 0   Definitivamente sí 
 1   Habitualmente 
 2   No muy seguido 
 3   Nunca 
  A D  
Siento como si estuviera más lento/a de lo habitual     
Casi todo el tiempo   3  
Muy frecuentemente   2  
Algunas veces   1  
Nunca   0  
Siento una especie de miedo, como si tuviera  
un nudo en el estómago 
 
   
Nunca  0   
Ocasionalmente  1   
Frecuentemente  2   
Muy frecuentemente  3   
He perdido interés en mi apariencia personal     
Definitivamente   3  
No me cuido tanto como debería   2  
Quizá no me cuido tanto como debería   1  
Me cuido igual que siempre   0  
Me siento inquieto/a, como si tuviera que  
estar en movimiento constante 
 
   
Muchísimo  3   
Mucho  2   
No mucho  1   
Nunca  0   
Espero las cosas con gusto     
Tanto como siempre   0  
Un poco menos de lo que solía  hacerlo   1  
Definitivamente menos de lo que solía hacerlo   2  
Casi nada   3  
Tengo sensaciones súbitas de miedo     
Muy frecuentemente  3   
Frecuentemente  2   
De vez en cuando  1   
Nunca  0   
Puedo disfrutar de un buen libro o de un  
programa de radio o televisión 
 
   
Con frecuencia   0  
Algunas veces   1  
No muy seguido   2  
Muy rara vez   3  
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GL Assessment Ltd  
Hospital Anxiety and Depression Scale (HADS) 
USER AGREEMENT 
 
Agreement Dated : ………………… 
1. LICENSEE’S NAME Please type all details and send back as Word doc attachment 
LICENSEE : : ………Luxana Reynaga-Ornelas………………..(note 1) .................................  
Address : Blvd. Puente del Milenio No.1001 Fracción Predio San Carlos. 
CP 37670. León Guanajuato. ............................................................................................  
Country : México 
VAT Number (if applicable) :    ..............................................................................(note 2)  
Contact Name if Different from above: 
Name : …………………………………………………….. 
Title : ………………………………………………......... 
Phone : ……………………………………………….. Fax :………….. 
Email ……………………………………………………………………….. 
Invoice Address if Different from above: (credit account form is required for invoicing – note 3) 
Universidad de Guanajuato. Lascurain de Retana No. 5. Guanajuato, Gto. CP 36000 RFC. 
450325-KY2 …… Credit Card Payments please phone 0845 602 1937 or fax to 0845 
601 5358 …………………...          
 READER CODE  (Mandatory- note 4)………………156581.................. 
  GL QUALIFICATION CODE   (Mandatory – note 4)…….10110…………… 
For student licensees the following are also required- (note 5): 
University Course and supervisor’s name : ………………………… 
Supervisor’s GL Reader Code 
Supervisor’s GL Qualification Code 
2. CONTEXT OF HADS USE    
 PROJECT (note 6): ……Dialysis Modality and Quality of Life of Persons with End 
Stage Renal Disease 
 Number of expected study participants :                                                       100 
 Number of administrations of the questionnaire per participant :                 1 
 TOTAL NUMBER OF ADMINISTRATIONS (note 7) :                              100 
 Planned study date: start 03     2011 end 08   2011 
    
3. STUDY FINANCING  
PLEASE INDICATE HERE IF YOUR USE OF HADS WILL BE FOR COMMERCIAL USE, 
OR ACADEMIC RESEARCH/NON-COMMERCIAL USE. (See FAQs in Permission 
 
month/year month/year 
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Information Doc for definitions) :  ……For academic research/non-commercial 
use………………………………  
 
Fee for commercial study:     0-1000 @ £0.55 each 
Price shown is per administration/use    0-2500 @ £0.50 each 
2500 + @ £0.45 each 
     
  
Fee for academic research/non-commercial use:  0-1000 @ £0.30 each 
Price shown is per administration/use    0-2500 @ £0.25 each 
2500 + @ £0.20 each 
Please Note: An additional administration fee of £50 will be applicable to orders 
under £50 
TOTAL COPYRIGHT FEE:  
£50………………………………………………………….…………………….. 
 
4. HADS VERSIONS & TRANSLATIONS (NOTE 9)  (THIS WILL BE SENT TO YOU  AS A PDF ATTACHMENT) 
 
DO YOU REQUIRE THE HADS IN ENGLISH? .............NO.................................................................................. 
 
IF SO, WHICH VERSION; ORIGINAL TEMPLATE, WORD, OR US VERSION? ………………………….. 
PLEASE INDICATE HERE IF YOU WILL REQUIRE TRANSLATIONS (A separate translation agreement will be 
required between the LICENSEE and the Mapi Research Trust and it is not part of this agreement). If 
appropriate, please indicate in which language(s) and for which country(ies) the HADS is needed:  
Languages: Spanish Mexico    
      
 
MEMORANDUM OF AGREEMENT, made on the date of this document between GL 
Assessment Limited of The Chiswick Centre, 414 Chiswick High Road, London W4 5TF 
(hereinafter called ‘the Publishers’) and the LICENSEE as defined on the first page of this 
agreement. 
NOW IT IS MUTUALLY AGREED between the parties hereto as follows: 
The Publishers hereby grants permission for the Licensee to reproduce in the printed format 
up to the TOTAL NUMBER OF ADMINISTRATIONS of the HOSPITAL ANXIETY AND 
DEPRESSION SCALE (HADS) (‘the Material’) subject to the following conditions to which 
the Licensee hereby agrees: 
1. The Licensee hereby agrees that the Material is to be used for the Licensee’s own 
research purposes only, and never under any circumstances for any commercial, 
non-research or other use unspecified in this Agreement.  
The specified use and purpose of the Material is for the PROJECT as defined on 
the front page of this agreement. 
 
2. The Licensee hereby agrees to pay to the Publishers the TOTAL COPYRIGHT FEE 
as defined above for the number of administrations detailed above.  Further 
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administrations over and above the specified amount may be negotiated as required 
on terms to be agreed. 
3. The Licensee will correspond with the MAPI Research Trust Contact@mapi-
trust.org regarding the availability of translated versions of the Material, if applicable. 
4. The Licensee will not make any changes to the Material as supplied by the 
Publishers or by the MAPI Research Trust, without first consulting the Publisher. 
5. The Licensee hereby agrees to delete the Word file containing the Material as soon 
as the agreed number of administrations have been reproduced. 
6. The Material must be returned to the Licensee, who is a qualified and registered 
GL Assessment test user in relation to the scoring and interpretation  of the 
data from the use of the Material.  The HADS manual shall be used for scoring 
and interpretation and is available by contacting the Publishers.    
7. The Licensee will include the following copyright and acknowledgement notice in full 
on each copy of the Material: 
HADS copyright © R.P. Snaith and A.S. Zigmond, 1983, 1992, 1994. 
Record form items originally published in Acta Psychiatrica Scandinavica 67, 361–70, copyright © 
Munksgaard International 
Publishers Ltd, Copenhagen, 1983. 
This edition first published in 1994 by nferNelson Publishing Company Ltd, 
414 Chiswick High Road, London W4 5TF 
GL Assessment is part of the Granada Group 
 
 This work may not be photocopied or otherwise reproduced by any means, even within 
the terms of a Photocopying Licence, without the written permission of the Publishers.  
8. The Material must not be reproduced in any publication or journal resulting from the 
research study nor should the Material be used in any other way other than that 
described above. 
9. The Licensee will send to the Publishers as soon as possible one copy of any 
published article, report or publication of the data collection and analysis resulting 
from the use of the Material. 
10. The Licensee agrees to exercise the utmost vigilance in protecting the Publishers’ 
copyright privileges on the material involved, both in the English language and as 
translated.  Unauthorised persons must not be given access to these materials and 
the copyright notice must appear in full on each copy of the Material. 
11. The Publishers cannot verify the accuracy of the Material or whether the Material 
has been validated or not. 
12. A person who is not a party to this Agreement has no rights under the Contracts 
(Rights of Third Parties) Act 1999 to enforce any term of this Agreement but this 
does not affect any right or remedy of a third party that exists or is available apart 
from that Act. 
13. The Licensee shall not assign or in any way transfer this licence without the prior 
written consent of the Publishers. 
14. This Agreement shall be terminated without further notice in any of the following 
circumstances: 
 
(a) If the Licensee fails to make any payment specified in this Agreement on 
the due date. 
 
(b) If the Licensee shall at any time be in breach of any of the terms and 
conditions of this Agreement and such breach is not remedied within 15 
days of receipt of written notice thereof. 
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